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ABSTRACT
Although severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in
humans primarily causes respiratory disease; some patients develop symptoms of neurological
disease, such as headache, loss of taste and smell, cognitive dysfunction, and impaired
consciousness. In this study, we analyzed the tissue tropism, immune response, and pathology in
human ACE2-expressing (hACE2) mice after SARS-CoV-2 infection. Intranasal infection of
hACE2 mice with SARS-CoV-2 resulted in a lethal disease with high levels of virus replication in
the brain tissue. SARS-CoV-2-infected mice exhibited encephalitis hallmarks characterized by
production of cytokines and chemokines, leukocyte infiltration, hemorrhage, and neuronal cell
death. SARS-CoV-2 was also found to productively infect cells within the nasal turbinate, eye,
and olfactory bulb, suggesting SARS-CoV-2 entry into the brain by this route after intranasal
infection.
NanoString gene expression analysis was performed to identify differentially expressed genes
(DEGs) in the brains of mice following SARS-CoV-2 infection. Genes that were upregulated after
infection were mainly associated with toll-like receptor (TLR) signaling, RIG-I like receptor
signaling (RLR) and cell death pathways, while down-regulated genes were associated with
neurodegeneration and synaptic signaling pathways. Next, we generated primary neuronal cultures
from hACE2 mice to investigate the effects of a SARS-CoV-2 infection. Our data show that
neuronal cultures obtained from hACE2 mice are permissive to SARS-CoV-2 infection and
support productive virus replication. Like the brain, SARS-CoV-2 infection upregulated the
expression of genes involved in innate immunity, inflammation, and necroptosis in the neurons.
Because age is a risk factor for COVID-19-related death in humans, we next evaluated the
pathogenesis of SARS-CoV-2 infection in yong and old mice. Our data show that intranasal

inoculation of SARS-CoV-2 in the older BALB/c mice resulted in severe disease, as evident by
rapid loss of body weight, gross and microscopic pathology of lungs, as well as elevated mRNA
levels of inflammatory cytokines and chemokines. In addition, our results indicate that a
diminished interferon response in the old mice may play a role in severe disease outcome observed
in these mice. Together, our data provide new insights into the pathogenesis of SARS-CoV-2
infection in mice.
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1

INTRODUCTION

The outbreak of novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
during late December 2019 in Wuhan, Hubei Province, China, has become a pandemic of global
concern, impacting human life and economic slowdown. The severity of SARS-CoV-2 infection
can be ascertained by an increased number of human deaths, specifically in older populations and
patients with predisposed cardiovascular disease (CVD) complications [1-4]. As of 12 January
2022, the number of confirmed cases worldwide is over 314 million, with 5.52 million deaths. A
few therapies are available to treat COVID-19 in patients; the rapid emergence of SARS-CoV-2
variants of concern (VOC) threatens to diminish their efficacy [3, 5, 6]. The exact origin, location,
and natural reservoir of the SARS-CoV-2 are unknown. It is thought to be zoonotic, and bats may
be reservoir due to sequence similarity to the bat-CoV. Previous epidemiologic investigations on
SARS-CoV-1 and MERS-CoV have found that the bat is the natural reservoir, whereas the palm
civet or raccoon dog may be the intermediate (or vulnerable) host for SARS-CoV-1 and the
dromedary camel for MERS-CoV [7].
SARS-CoV-2 infection in humans can cause pneumonia, acute respiratory distress
syndrome, acute lung injury, cytokine storm syndrome and death [8, 9]. Although SARS-CoV-2
infection primarily causes respiratory disease, some patients develop symptoms of neurological
disease, such as headache, loss of taste and smell, ataxia, meningitis, cognitive dysfunction,
memory loss, seizures and impaired consciousness [10-16]. SARS-CoV-2 infection also induces
long-term neurological sequelae in at least one-third of human cases. Infection with other
coronaviruses, such as mouse hepatitis virus (MHV) in mice and SARS-CoV-1 and Middle East
Respiratory Syndrome (MERS) virus in humans, has been shown to cause neurological disease
[17, 18]. Infection of central nervous system (CNS) cells by other coronaviruses has been reported.
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For example, SARS-CoV-1 is proposed to enter the brain via the olfactory bulb resulting in the
rapid trans neuronal spread and minimal cellular infiltration [19]. HCoV-OC43 can cause
meningoencephalitis and acute disseminated encephalitis [20, 21]. Whereas MERS-CoV has been
reported to cause Bickerstaff brainstem encephalitis and disseminated encephalitis [21-23].
However, little is known about the pathophysiology of SARS-CoV-2-associated neurological
disease in humans.
SARS CoV-2 binds to Angiotensin-Converting Enzyme-2 (ACE2) receptors on host cells,
followed by its internalization, rapid multiplication, and instigate cytokine storm. CNS cells that
express the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) include neurons,
glial cells and astrocytes [24, 25]. ACE2 is expressed in multiple human brain areas, including the
amygdala, cerebral cortex and brainstem, with the highest expression levels found in the pons and
medulla oblongata in the brainstem that contain the medullary respiratory centers of the brain [10,
26]. Several human autopsy reports have documented the presence of SARS-CoV-2 RNA in brain
tissues [27, 28]. Human iPSC-derived neural progenitor cells (NPCs) have been shown to be
permissive to SARS-CoV-2 infection, and both viral proteins and infectious viral particle
production were detected in neurospheres and brain organoids infected with SARS-CoV-2 [29,
30]. Human autopsy reports have shown evidence of lymphocytic panencephalitis, meningitis and
brainstem perivascular and interstitial inflammatory changes with neuronal loss in COVID-19
patients [31].These data suggest that SARS-CoV-2 can productively infect human CNS cells [32].
However, the contributions of CNS cell infection and induced neuroinflammation to the
pathogenesis of SARS-CoV-2-associated disease are not well understood.
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1.1

SARS-CoV-2 Structure and genomic organization
The non-segmented positive-sense RNA genome of Coronaviruses (CoV) is the largest

genome among all RNA viruses with approximately 30 Kb in size. Spike-like structures on the
outer envelope of a CoV are a characteristic feature of this virus. The virus particle has four
structural proteins, namely spike (S), membrane (M), envelope (E) and, nucleocapsid (N) proteins
[33]. Functionally, S protein facilitates virus attachment to the host cell surface receptors and
internalization of virus inside the host cell. S protein is the most abundant glycoprotein. M protein
is required for virus assembly and maintains the shape of the viral envelope. Assembly and release
of the virus particle require the interaction between less abundant proteins E and M [34, 35].
According to Stohlman et al., deletion of the E gene attenuates the virus as the E gene encodes a
small multifunctional protein with ion channel activity, which plays an essential role in virus-host
interaction [36]. N protein is the sole nucleocapsid protein, which has N terminal and C terminal
domains. It has been suggested that N protein is heavily phosphorylated, and this triggers a
structural change that enhances the viral RNA replication [36, 37].
1.2

COVID-19 Outbreak and treatment options
It is the first time that a coronavirus has caused a pandemic in humans. However, there are

reports of previous outbreaks caused by other CoV members, such as SARS-CoV-1 and MERSCoV. The current pandemic's causative agent is SARS-CoV-2 [8], that affects human circulatory
and respiratory systems. The rapid progression of the disease and its higher transmission rate
makes it a severe global health concern. Infected patient present symptoms, such as fever, body
ache, tiredness, difficulty breathing, and lung infection with pneumonia-like symptoms. Currently,
more than 185 countries have contacted the disease outbreak [38]. The major challenge in front of
the medical healthcare system and scientists is to contain the disease via social distancing and
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utilizing already available drugs approved by the Food and Drug Administration (FDA). There is
an urgent need to establish fundamental knowledge and understanding of the host-pathogen
interaction to exploit more effective treatment options. Therefore, it is critical to understand the
pathogenesis of the virus and its target cells, including the immune response to the virus
replication. To date, there are only few approved drugs to treat a coronavirus infection. Several
drugs such as Remdesivir, Lopinavir/Ritonavir and Flavipiravir have been shown to be very
effective in inhibiting SARS CoV-2 infection [8, 39]. Remdesivir is a nucleotide analog previously
used in the treatment of the Ebola outbreak in Africa and is currently used in the treatment of
COVID-19. A study conducted by Grein et al., with 61 patients from the United States, Europe,
and Japan, were administrated 200 mg Remdesivir through IV on day one followed by 100 mg for
the next nine days. At the end of the study, 36 patients out of 53 showed clinical improvements
[40]. On May 1, 2020, the FDA issued an Emergency Use Authorization (EUA) for Remdesivir.
That means the FDA has not yet approved Remdesivir for treating COVID-19 patients; however,
the drug is easily accessible to doctors for the urgent need of COVID-19 hospitalized patients. On
June 1, 2020, Gilead pharmaceutical announced Phase 3 clinical trial results in which the
Remdesivir is found to improve the condition in moderate COVID-19 patients. However, still more
data and extensive studies are required. Proteases are fundamental for virus replication. Protease
inhibitors can also inhibit SARS-CoV-2 viral replication by inactivating the proteases.
Lopinavir/Ritonavir is currently used in the emergency management plan for COVID-19.

Increased cytokine levels and inflammatory response due to the SARS-CoV-2 infection are
among the most critical causes of organ damage. Abnormal release of proinflammatory cytokines,
mainly IL-6, TNF-α, and IFN-γ , contributes to cytokine release syndrome. Tocilizumab is a drug
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used for the treatment of inflammatory conditions like rheumatoid arthritis. Inflammation is a
natural response of our immune system against harmful pathogens. Sometimes due to the
overactive immune system, inflammations go haywire, causing cytokine storms in which the
immune system works against our own body. IL-6 is a major inflammatory cytokine, and
Tocilizumab helps attenuate inflammation by blocking the IL-6 receptor [41, 42]. Corticosteroids
are anti-inflammatory drugs that are also used for COVID-19 treatment. Published literature
suggests thromboembolic manifestations associated with COVID-19. Activation of the
coagulation cascade and endothelial injury are indicated as a cause for the development of a
prothrombotic state associated with an exaggerated pro-inflammatory response. The use of
anticoagulants such as heparin remains an area of conjecture with no definite guidelines of its
usage [43].
Convalescent plasma (CP) is another treatment method in COVID-19 patients in which
blood plasma of infected patients is infused in another COVID-19 patient. Patients recovered from
COVID-19 carry the SARS-CoV-2 specific antibody in their blood. Therefore, already built
antibodies from recovered patients serve as a therapeutic alternative to treat SARS-CoV-2 infected
patients [44]. A study of 10 adult patients showed that 200 ml of CP effectively cleared viral load
in 7 days. On May 1, 2020, FDA issued an application of Emergency Investigational New Drug
(eIND) for CP as the COVID-19 treatment option. However, larger-scale research and random
trials are required before making any final conclusion [45].
1.3

ACE-2 Receptor and Function
SARS CoV-2 binds to Angiotensin-Converting Enzyme-2 (ACE2) receptors on host cells,

followed by its internalization and replication. ACE2 has a cardioprotective role, and SARS-CoV2 internalization into cells has been reported to downregulate ACE2 expression [46-50]. In the
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normal adult lung, ACE2 is primarily expressed in primary alveolar epithelial type II cells and
plays a protective role in the lungs. Surfactant proteins produced by these cells help reduce surface
tension and protect alveoli from collapsing [51, 52]. Ang II (Angiotensin II) is the main effector
molecule in the RAAS (renin-angiotensin-aldosterone system) pathway, which is upregulated in
many diseases and it’s a common target in various cardiovascular disorders [53]. ACE-2 helps
inactivate Ang II by converting Ang II to Ang (1-7) [54]. According to a recent study, exogenous
administration of recombinant human ACE2 (rhACE-2) can prevent SARS-CoV-2 infection by
acting as a decoy. hrACE2 effectively reduced the infection in cell culture and human blood vessels
organoids and kidney organoids. The protective role of hrACE-2 has been reported by different
groups in CVDs, rhACE2 could be a promising treatment option for CVD patients with COVID19 infection [37, 54, 55]. ACE inhibitors/angiotensin receptor blockers (A.C.E.Is/A.R.Bs) are
increasingly used in CVD treatments, and according to studies, they help upregulate ACE-2
expression. The fact that ACE-2 expression could correlate with SARS-CoV-2 susceptibility and
intake may predispose CVD patients to increased risk of SARS-CoV-2 infection. Therefore, the
usage of such drugs should be very carefully evaluated in CVD patients [56].
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Figure 1: The SARS CoV-2 binds to ACE2 receptor on endothelial cells by its S
protein. ACE2 has a cardioprotective effect. On the contrary, increased ANG II in the absence of
ACE2 increases the risk of CVD. SARS CoV-2, Severe Acute Respiratory Syndrome Coronavirus
2; S protein, Spike protein; ANG, Angiotensin; AT1R, Angiotensin 1 receptor; NO, nitric oxide;
ROS, reactive oxygen species.

1.4

SARS-CoV-2 and Variants of Concern (VOC)
Large genome size and the mutation tendency have resulted in a divergence of coronavirus

strains capable of higher infectivity and increased adaptation to new hosts [2]. The lineage B.1.1.7
was first identified in the United Kingdom, lineage B.1.352 was discovered in South Africa, and
lineage B.1.617.2 was described in India. These variants have been termed VOC because of the
higher risk due to their possible enhanced transmissibility, disease severity, and immune escape
[6, 57]. These variants may adapt to new hosts, in part, through mutations on the receptor-binding
domain (RBD) of spike (S) protein [58].
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The SARS-CoV-2 infection starts with the binding of S protein to the host cell surface receptor.
RBD of S protein binds to the angiotensin-converting enzyme (ACE2) receptor on the human cell
surface to facilitate the virus entry into the host [4, 59]. The RBD of S protein from the SARSCoV-2 (Wuhan strain, lineage B.1) does not efficiently bind the mouse ACE-2; wild-type
laboratory mice are not suitable for infection with lineage B.1 virus [60-64]. MA10 is a mouseadapted variant of SARS-CoV-2 with binding affinity to mouse ACE2 that has been obtained after
sequential passaging of the virus in mouse lungs tissue [63]. MA10 infection in wild-type BALB/c
mice resulted in virus replication in the upper and lower airways [63-65]. The MA10 virus has
several mutations, including multiple mutations in the S protein compared with the Wuhan (B.1)
reference sequence. These mutations are also present in B.1.1.7 and B.1.351 lineage, which
emerged independently of B.1.1.7 lineage. B.1.1.7 variant has a mutation in the RBD region,
including N501Y, 69/70 deletion, and P681H near the S1/S2 furin cleavage site. The B.1.351
variant has eight mutations, of which the three most notable mutations are K417N, E484K, and
N501Y in the S protein. The B.1.617.2 variant has three unique mutations, E156del/R158G in the
N-terminal domain and T478K in RBD of S protein [57, 66-69]. Compared to eight or three
mutations in known variants, Omicron; recently identified strain carriers fifty mutations on spike
(S)-protein [70]. These mutants are associated with critical public health concerns in the current
scenario.
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2.1

DISSERTATION SCOPE

Background and rationale
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome

coronavirus-2 (SARS-CoV-2) continues to be a global concern. In addition, several variants of
SARS-CoV-2 have been identified that may influence antibody treatment and vaccine efficiency
[8, 9, 71, 72]. Neurological complications, including cerebrovascular injury, altered mental status,
encephalitis, encephalopathy, dizziness, headache, loss of taste and anosmia have been reported in
some patients [10, 11, 17, 32, 73]. Further, human autopsy reports have shown evidence of
lymphocytic panencephalitis, meningitis, brainstem perivascular and interstitial inflammatory
changes with neuronal loss in COVID-19 patients [31, 32]. As such, viral RNA has been detected
in brains of some COVID-19 cases, suggesting the olfactory mucosa could be a port of virus entry
[28, 32, 72, 74, 75]. Angiotensin-converting enzyme 2 (ACE2), the entry receptor of SARS-CoV2, is widely detected in the brain and is highly concentrated in several brain regions, including the
substantia nigra, middle temporal gyrus and posterior cingulate cortex [10, 24, 76-79]. However,
little is known about the causes of the SARS-CoV-2-induced neurological disease in humans. In
addition, there is a lack of robust and practical in vivo and in vitro model systems to investigate
the neuropathogenesis of a SARS-CoV-2 infection.
The overall goal of this proposal is to characterize in vivo and in vitro model systems for
investigating neuropathogenesis caused by SARS-CoV-2 infection, including neuroinflammation
and neuronal cells dysfunction. We hypothesize that SARS-CoV-2 can productively infect and
replicate into the neuronal cells, inducing neuroinflammation and neuronal cell dysfunction and
death.
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2.2

Specific aims
Specific Aim 1: To characterize in vivo and in vitro model systems for investigating

SARS-CoV-2-induced neuropathogenesis: It is known that wild-type mice do not support the
replication of SARS-CoV-2. As such, the transgenic mice expressing hACE2 under the cytokeratin
18 promoter (K18-hACE2) represent a lethal model of SARS-CoV-2 infection [80-84]. In this aim,
we will evaluate the kinetics of SARS-CoV-2 infection, tissue tropism and pathology in K18hACE2 mice. In addition, we will generate primary cortical neuronal cultures from K18-hACE2
mice to investigate the neurotoxic effects of a SARS-CoV-2 infection in neurons.
Specific Aim 2: To investigate the immunological response to SARS-CoV-2 infection in
the mouse brain and primary neuronal cultures.
Sub-Aim 2.1: To examine the global immune response of SARS-CoV-2 infection in the
brain: A better understanding of the global gene changes underlying the multi-step progression of
pathogenicity during infection could help develop potential therapeutic strategies for SARS-CoV2. We will use nanostring technology to determine expression levels of various mRNA genes in
SARS-CoV-2-infected mouse brain.
Sub-Aim 2.2: To study the effects of a SARS-CoV-2 infection in the primary neurons of
human ACE2-expressing mice: Increased mortality has been linked to neuroinvasion and SARSCoV-2 replication in the CNS of K18-hACE2 mice, although the mechanism remained unclear.
We will generate primary neuronal cultures from K18-hACE2 mice to investigate the effects of a
SARS-CoV-2 infection in the neurons. We will explore the activation of various immune,
inflammatory and cell death pathways in the SARS-CoV-2-infected neurons.
Specific Aim 3: To analyze the pathogenesis of a SARS-CoV-2 infection in the aged
mice: The older population is at high risk of coronavirus infections with increased disease severity
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and pathogenicity. Inflammaging, a process that favors a constant low-grade pro-inflammatory
environment in the older population, may contribute to adverse effects. We will do a comparative
study to characterize the pathogenicity of SARS-CoV-2 infection in the different age groups of
mice.
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3

NEUROINVASION AND ENCEPHALITIS FOLLOWING INTRANASAL
INOCULATION OF SARS-COV-2 IN K18-HACE2 MICE
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can cause

neurological disease in humans, but little is known about the pathogenesis of SARS-CoV-2
infection in the central nervous system. Herein, using K18-hACE2 mice, we demonstrate that
SARS-CoV-2 neuroinvasion and encephalitis is associated with mortality in these mice.
Intranasal infection of K18-hACE2 mice with 105 plaque-forming units of SARS-CoV-2 resulted
in 100% mortality by day 6 after infection. The highest virus titers in the lungs were observed at
day 3 and declined at days 5 and 6 after infection. In contrast, very high levels of infectious virus
were uniformly detected in the brains of all the animals at days 5 and 6. Onset of severe disease
in infected mice correlated with peak viral levels in the brain. SARS-CoV-2-infected mice
exhibited encephalitis hallmarks characterized by production of cytokines and chemokines,
leukocyte infiltration, hemorrhage and neuronal cell death. SARS-CoV-2 was also found to
productively infect cells within the nasal turbinate, eye and olfactory bulb, suggesting SARSCoV-2 entry into the brain by this route after intranasal infection. Our data indicate that direct
infection of CNS cells together with the induced inflammatory response in the brain resulted in
the severe disease observed in SARS-CoV-2-infected K18-hACE2 mice.
3.1

Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in humans can

cause pneumonia, acute respiratory distress syndrome, acute lung injury, cytokine storm syndrome
and death [8, 9]. Although SARS-CoV-2 infection primarily causes respiratory disease; some
patients develop symptoms of neurological disease, such as headache, loss of taste and smell,
ataxia, meningitis, cognitive dysfunction, memory loss, seizures and impaired consciousness [10,
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11, 85-90]. SARS-CoV-2 infection also induces long-term neurological sequelae in at least onethird of human cases. Infection with other coronaviruses, such as mouse hepatitis virus (MHV) in
mice, and SARS-CoV-1 and Middle East Respiratory Syndrome (MERS) in humans have been
shown to cause neurological disease [17, 91]. However, little is known about the pathophysiology
of SARS-CoV-2-associated neurological disease in humans.
Central nervous system (CNS) cells that express the SARS-CoV-2 receptor, angiotensinconverting enzyme 2 (ACE2), include neurons, glial cells and astrocytes [24, 76]. ACE2 is
expressed in multiple human brain areas, including the amygdala, cerebral cortex and brainstem
with the highest expression levels found in the pons and medulla oblongata in the brainstem that
contain the medullary respiratory centers of the brain [10, 77]. Several human autopsy reports have
documented the presence of SARS-CoV-2 RNA in brain tissues [28, 72]. Human iPSC derived
neural progenitors cells (NPCs) have been shown to be permissive to SARS-CoV-2 infection and
both viral proteins and infectious viral particle production were detected in neurospheres and brain
organoids infected with SARS-CoV-2 [92, 93]. Human autopsy reports have shown evidence of
lymphocytic panencephalitis, meningitis and brainstem perivascular and interstitial inflammatory
changes with neuronal loss in COVID-19 patients [31]. These data suggest that SARS-CoV-2 can
productively infect human CNS cells [32]. However, the contributions of CNS cell infection and
induced neuroinflammation to the pathogenesis of SARS-CoV-2-associated disease are not well
understood. Small animal models provide a means for studying the neurological complications
associated with SARS-CoV-2 infection. K18-hACE2 is a transgenic mice model which expresses
human ACE-2 driven by human cytokeratin 18 promoter. K18-hACE2 mice model was originally
developed to study SARS-CoV pathogenesis [94].It was recently reported that intranasal
inoculation with SARS-CoV-2 results in a rapidly fatal disease in K18-hACE2 mice [81-84].
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These studies were focused on describing the acute lung injury in SARS-CoV-2 infected K18hACE2 mice that was associated with high levels of inflammatory cytokines and accumulation of
immune cells in the lungs [81-84]. In these published studies, infectious virus or viral RNA was
not detected in the olfactory bulbs or brains of the majority of the infected animals, indicating
restricted neurotropism of SARS-CoV-2 in K18-hACE2 mice. In the present study, we show that
intranasal infection of six-week-old K18-hACE2 mice by SARS-CoV-2 can cause severe
neurological disease with the brain being a major target organ for infection by this route of
infection and neuroinflammation and neuronal death contributing to the infection-associated
morbidity and mortality. The data also suggest that the SARS-CoV-2 can be trafficked to the brain
via the olfactory bulb with subsequent transneuronal spread, as has been reported for other
coronaviruses [95, 96].
3.2

Materials and Methods
3.2.1

Mice

Hemizygous K-18 hACE2 mice were purchased from the Jackson Laboratory (Bar Harbor,
ME). All the animal experiments were conducted in a certified animal biosafety level-3 (ABSL-3)
laboratory at the Georgia State University (GSU). The protocol was approved by the GSU IACUC
(Protocol number A20044). Six-week-old hemizygous K-18 hACE2 mice were infected with 105
plaque-forming units (PFU) of SARS-CoV-2 strain USA-WA1/2020 under ABSL-3 containment
by intranasal inoculation. SARS-CoV-2 (USA-WA1/2020) was isolated from an oropharyngeal
swab from a patient in Washington, USA (BEI NR-52281) [97]. Animals in the control group
received equivalent amounts of sterile PBS via the same route. Roughly equal numbers of male
and female mice were used. Animals were weighed and their appetite, activity, breathing and
neurological signs assessed twice daily [98, 99]. Mice that met the human endpoint criteria were
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euthanized to limit suffering. In independent experiments, mice were inoculated with PBS (Mock)
or SARS-CoV-2 intranasally, and on days 1, 3, 5 and 6 after infection, animals were anesthetized
using isoflurane, perfused with cold PBS and respiratory (nasal turbinate and lung) and other
tissues (spleen, heart, liver, kidney, pancreas, eye, olfactory bulb and brain) were collected and
flash frozen in 2-methylbutane (Sigma, St. Louis, Missouri, United States) [100-102].
Alternatively, mice were perfused with PBS followed by 4% paraformaldehyde (PFA) and tissues
were harvested, cryoprotected in 30% sucrose (Sigma, St. Louis, Missouri, United States), and
embedded in optimum cutting temperature (OCT) as described previously [100, 103].
3.2.2

Quantification of the virus load

The virus titers were analyzed in the tissues by plaque assay and quantitative real-time PCR
(qRT-PCR) [97, 98]. Briefly, frozen tissues were weighed and homogenized in a bullet blender
(Next Advance, Averill Park, New York, United States) using glass or zirconium oxide beads.
Virus titers in tissue homogenates were measured by plaque assay using Vero cells. Quantitative
RT-PCR was used to measure viral RNA levels using primers and probes specific for the SARSCoV-2 N gene as described previously [97]. Viral genome copies were determined by comparison
to a standard curve generated using a known amount of RNA extracted from previously titrated
SARS-CoV-2 samples. Frozen tissues harvested from mock and infected animals were weighed
and lysed in RLT buffer (Qiagen) and RNA was extracted using a Qiagen RNeasy Mini kit
(Qiagen, Germantown, MD, USA). Total RNA extracted from the tissues was quantified,
normalized and viral RNA levels per μg of total RNA were calculated.
3.2.3

Measurement of cytokines, chemokines and interferons

The levels of mRNA for select cytokines/chemokines (IL-1β, IL-6, TNF-α, IFN-γ, CCL2 and
CCL3) and interferon-α (IFN-α) were determined in total RNA extracted from the lungs and brain
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using qRT-PCR. The fold-change in infected tissues compared to mock tissues was calculated after
normalizing to the GAPDH gene [100, 103]. The primer sequences and annealing temperatures
used for qRT-PCR are listed in Table 1. The protein levels of IFN-α were measured in the lung
and brain homogenates using an ELISA kit (PBL Interferon Source, Piscataway, NJ, USA) [98,
99].
Table 1: Primer sequences used for qRT-PCR.

Gene (Accession
Primer Sequence (5'-3')
No.)
IL-1β (NM_000576)
AGCACCTTCTTTCCCTTCAT
Forward
C
Reverse

GGACCAGACATCACCAAGC

IL-6 (NM_000600)
CCAGGAGCCCAGCTATGAA
Forward
C
Reverse

CCCAGGGAGAAGGCAACTG

CCL3
(NM_011337)
Forward

ATTCCACGCCAATTCATC

Reverse

ATTCAGTTCCAGGTCAGT

IFN-α
(NM_010502)
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Forward

CTCTGTGCTTTCCTGATG

Reverse

CTGAGGTTATGAGTCTGAG

TNF-α
(NM_013693)
Forward

CCAGTCTGTATCCTTCTAA

Reverse

TCTTGTGTTTCTGAGTAGT

CCL2
(NM_011333)
TCACCTGCTGCTACTCATTC
Forward
ACCA
TACAGCTTCTTTGGGACAC
Reverse
CTGCT
IFN-γ
(NM_008337)
TTCACTGACCAATAAGAAA
Forward
C
Reverse
3.2.4

TACTACCTGACACATTCG

Immunohistochemistry

Sagittal sections (10-μm thick) were cut from the hemi-brain tissues frozen in OCT. Tissue
sections were stained with hematoxylin and eosin (H&E) for histopathological evaluation [103,
104]. Additionally, tissue sections were incubated with anti-CD45, anti-NeuN and anti-SARSCoV-2 spike protein antibodies (Thermo Fisher Scientific, Norcross, GA, USA) overnight at 4°C
followed by incubation with Alexa Fluor 546- or Alexa Fluor 488-conjugated secondary antibody
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for 1 hr at room temperature [100, 103]. Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining was conducted using an in-situ cell death detection kit (Roche,
Indianapolis, Indiana, United States) as per the manufacturer’s instructions [100, 103]. Images
were acquired using the Invitrogen™ EVOS™ M5000 Cell Imaging System (Thermo Fisher
Scientific, Norcross, GA, USA).
3.2.5

Statistical Analysis

An unpaired Student’s t-test was used to calculate p values of significance. Differences with
P values of <0.05 were considered significant.
3.3

Results
3.3.1

Characteristics of K18-hACE2 mice following SARS-CoV-2 infection by the
intranasal route

Six-week-old K18-hACE2 mice of both sexes were infected intranasally with PBS (mock,
n=10 mice) or 105 PFU of SARS-CoV-2 in PBS (n=20 mice). The mock-infected mice remained
healthy throughout the observation period. Virus infection resulted in 100% mortality by day 6
after infection (Figure 1A). Infected mice experienced significant weight loss on days 4 through 6
after infection compared to the mock-infected group (Figure 1B). Starting on day 4, all the infected
animals began to show signs of disease, such as lethargy, slow movement and labored breathing.
Neurological symptoms, such as hunchbacked posture, ruffled fur, tremors and ataxic gait, were
also observed in infected mice on days 5 and 6 after infection.
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Figure 2: Analysis of survival, body weight and virus titers in K18-hACE2 mice
following SARS-CoV-2 infection. K18-hACE2 mice were inoculated intranasally with SARSCoV-2 (105 PFU, n=20) or PBS (Mock, n=10). (A) Percent survival was determined. (B) Percent
daily body weight change in the animals. Error bars represent SEM. **p < 0.001. The kinetics and
levels of SARS-CoV-2 were determined in the lungs (C and D) and brain (E and F) by plaque
assay and qRT-PCR. The data are expressed as PFU/g of tissue or genome copies/μg of RNA.
Each data point represents an individual mouse. The solid horizontal lines signify the median.

3.3.2

Virus replication in the periphery and brain of K18-hACE2 mice

Six-week-old K18-hACE2 mice of both sexes were infected intranasally with PBS (mock,
n=12 mice) or 105 PFU of SARS-CoV-2 in PBS (n=20 mice) and groups of 5 mice were used to
measure the viral loads in the peripheral organs and brain at early (day 1), middle (day 3) and late
(days 5 and 6) stages of infection. High virus levels were observed in the lungs on day 1, reached
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peak levels at day 3 and declined at days 5 and 6 after infection (Figures 1C and 1D). In contrast,
virus was not detected in the brain on day one but was present by day 3 after infection. Very high
levels of viral RNA and infectious virus were detected in the brains of all the animals by days 5
and 6 after infection (Figures 1E and 1F). The onset of neurological symptoms and mortality in
infected mice correlated with peak virus titers in the brain.
The virus replication kinetics observed in the nasal turbinates was similar to those in the lungs
with the highest viral RNA levels detected during the early stage of infection (days 1 and 3),
followed by a decline at later stages of infection (days 5 and 6) (Figure 2). In the olfactory bulbs
and eyes, low levels of viral RNA were detected on days 1 and 3 after infection, with very high
levels of viral RNA detected in all the animals on days 5 and 6 after infection indicating productive
infection within the olfactory system (Figure 2). In contrast, little if any virus was detected in the
serum of infected mice at any time after infection tested.
Since the K18 promoter is known to be active in the epithelium of multiple organs of K-18hACE2 mice [96, 105], we also evaluated viral RNA levels in other peripheral organs. Viral RNA
was detected in the heart, kidney, spleen, pancreas and liver on days 1 and 3. There was a slight
increase in RNA levels on days 3 and 5 in each of these organs, suggesting limited virus replication
at these sites (Figure 2). These data agree with previous reports that also showed the presence of
SARS-CoV-2 RNA in these organs [81-84, 96, 105].
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Figure 3: Analysis of virus tropism in K18-hACE2 mice. The viral RNA copy number
in the nasal turbinates, olfactory bulbs, eye, serum, kidney, spleen, pancreas, heart and liver was
determined on days 1, 3, 5 and 6 after infection by qRT-PCR and expressed as genome copies/μg
of RNA. Each data point represents an individual mouse. The solid horizontal lines signify the
median.

3.3.3

Inflammatory changes in the lungs and brain of SARS-CoV-2-infected mice

IFN signaling has a pivotal role in developing an innate and adaptive immune response to
viral infection [106, 107]. Therefore, we measured the mRNA and protein levels of IFN-α in the
lungs and brain. In the lungs, an increase in both IFN-α mRNA and protein levels was detected on
day 1, peaked at day 3 and then decreased on day 6 after infection (Figures 3A and 3B). In contrast,
an IFN response was not detected in the brain on days 1 and 3 after infection. High levels of IFN-
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α were detected in the brain only by days 5 and 6 after infection (Figures 3C and 3D). Overall, the
induction of IFN-α correlated with the SARS-CoV-2 replication kinetics in the lungs and brain. It
is interesting to note that relative IFN-α levels were comparatively higher in the lungs compared
to the brains of the infected animals despite higher virus replication in the brain.

Figure 4:Analysis of mRNA and protein levels of IFN-α in the lungs and brain. The
mRNA levels of IFN-α were measured in the lungs (A) and brain (C) by qRT-PCR, and the fold
change in the infected tissues compared to the corresponding mock-infected controls was
calculated after normalizing to the GAPDH gene. The protein levels of IFN-α were measured in
the lungs (B) and brain (D) homogenates using ELISA and expressed as pg/g of tissue. Error bars
represent SEM (n = 5 mice per group). *p < 0.05; **p < 0.001.

We next examined the mRNA levels of proinflammatory cytokines and chemokines in the
lungs and brain of infected mice. SARS-CoV-2 infection resulted in a 10-fold increase on day 1
and a 100-fold increase on day 3 in the IL-6 mRNA expression in the lungs (Figure 4A). The levels
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of TNF-α mRNA were elevated ~10-fold in the lungs on day 1 and 3 after infection. The level of
IFN-γ mRNA was elevated by 15-fold on day 3. However, the levels of these cytokines had
decreased by day 5 after infection. The IL-1β mRNA levels showed no significant increase at any
time point after infection. There was a 100-fold increase in the expression of CCL2 on day 3
(Figure 4B). However, the levels of CCL2 mRNA had decreased by day 5 after infection. CCL3
mRNA levels increased slightly on day 1 and were undetectable at days 5 and 6 after infection.
In the brain, no increase in the mRNAs of the cytokines or chemokines tested was observed
on day 1 after infection. Less than a 10-fold increase was observed in the cytokine mRNA levels
on day 3 (Figures 4C). There was a 500-fold increase in IL-6 mRNA by day 5 after infection. TNFα and IFN-γ mRNA levels increased by ~ 750-fold in the brain by day 5 after infection. Similarly,
IL-1β mRNA levels increased by 400-fold by day 5 after infection. Both CCL2 and CCL3 mRNA
levels were elevated by almost 1,000-fold on days 5 and 6 after infection and consistent with the
high level of virus in the brain (Figure 4D). These results indicate that the inflammatory response
was more pronounced in the brain than in the lungs at the later stage of infection.
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Figure 5: Cytokine and chemokine mRNA level in the lungs and brain. The mRNA
levels of various cytokine and chemokine genes were determined in the lungs (A and B) and brain
(C and D) using qRT-PCR. Fold change in the infected tissues compared to the corresponding
mock controls was calculated after normalizing to GAPDH mRNA in each sample. Error bars
represent SEM (n = 5).

3.3.4

SARS-CoV-2 induced neuropathology in K18-hACE2 mice

We next analyzed the brain sections from infected mice for antigen distribution, infiltration of
immune cells and cell death. Immunohistochemical staining for the SARS-CoV-2 spike protein
detected cell-associated viral antigen throughout the brain at day 6 after infection. Representative
data for sections from the cortex, cerebellum and hippocampus regions are shown in figure 5. We
also detected virus antigen in sections of the olfactory bulb of infected animals on day 6. H&E
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staining of brain sections from the infected mice demonstrated perivascular hemorrhage and
neuronal cell death (Figures 6A and 6B). The neurons of infected mice demonstrated shrunken
neuron body with light pink cytoplasmic staining representing degenerating neurons (Figure 6B).
Enhanced leukocyte infiltration was detected within blood vessel walls and in the perivascular
space

(Figure

6A).

Evidence

of

leukocyte

infiltration

was

confirmed

by

direct

immunohistochemical analysis of the CD45 antigen, which revealed many CD45-positive cells in
the brain parenchyma near neurons (Figure 6C). SARS-CoV-2-induced cell death was evaluated
by direct TUNEL staining of brain tissues. On day 6, infected K18-hACE2 mice had elevated
numbers of TUNEL-positive cells in the cortex, hippocampus and cerebellum regions, indicating
increased cell death (Figure 6D).
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Figure 6: Detection of SARS-CoV-2-infected cells in the brains of K18-hACE2
transgenic mice. Brain sections (day 6 after infection) were stained for SARS-CoV-2 spike
protein. Representative immunostaining images showing the presence of SARS-CoV-2 spike
protein (red) in the cortex, cerebellum, hippocampus and olfactory bulb of infected mice. Nuclei
are stained with DAPI (blue). The photomicrographs shown are representative of the images
obtained from five animals. Bars, 20 μm.
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Figure 7: Histopathological analysis of SARS-CoV-2-infected brains. H&E staining of
brain sections from mock and SARS-CoV-2-infected mice at day 6 after infection. (A and B) Brain
sections show perivascular hemorrhage, enhanced leukocyte infiltration (blue arrows) and
neuronal cell death (red arrows). (C) Brain sections were stained for CD45 (Red, leukocyte marker)
and NeuN (Green, neuronal cell marker). Nuclei are stained with DAPI (blue). (D) A TUNEL
assay was conducted on brain sections from mock and SARS-CoV-2-infected mice at day 6 after
infection to detect apoptotic cells. The boxed areas in the second row of panels are enlarged in the
bottom row of panels. The photomicrographs shown are representative of the images obtained
from five animals. Bars, 20 μm.

3.4

Discussion
This study demonstrates a critical role of direct infection of CNS cells and of the inflammatory

response in mediating SARS-CoV-2-induced lethal disease in K18-hACE2 mice. Intranasal
inoculation of the virus results in a lethal disease with high levels of virus replication in the brain.
Virus infection of the CNS was accompanied by an inflammatory response as indicated by the
production of cytokines/chemokines, infiltration of leukocytes into the perivascular space and
parenchyma and CNS cell death. Our data also indicate that following infection by the intranasal
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route, the virus enters the brain by traversing the cribriform plate and infecting neuronal processes
located near the site of intranasal inoculation.
Some animal coronaviruses, such as MHV readily infect the neurons and cause lethal
encephalitis in mice [91, 108]. SARS-CoV infection also induces severe neurological disease after
intranasal administration in K18-hACE2 mice [96]. Similarly, in our study, SARS-CoV-2 virus
antigen was detected throughout the brain, including the cortex, cerebellum and hippocampus. The
onset of severe disease in SARS-CoV-2 infected mice correlated with peak viral levels in the brain
and immune cell infiltration and CNS cell death. Peak virus titers in the brains were approximately
1,000 times higher than the peak titers in the lungs, suggesting a high replicative potential of
SARS-CoV-2 in the brain. The relative up-regulation of cytokine and chemokine mRNAs was
approximately 10 to 50 times higher in the brain compared to the lungs, strongly suggesting that
extensive neuroinflammation contributed to clinical disease in mice.

It was recently reported that SARS-CoV-2 infection of K18-hACE2 mice causes severe
pulmonary disease with high virus levels detected in the lungs of these mice and that mortality was
due to the lung infection [81-84]. In these studies, viral RNA was undetectable in the brains of the
majority of the infected animals, indicating a limited role of brain infection in disease induction.
An important distinction between our study and others is that we detected high infectious virus
titers in the olfactory system and brains of 100% of the infected K18-hACE2 mice. This phenotype
was not consistently observed in the aforementioned K18-hACE2 mouse studies [81-84].
Moreover, none of the published studies evaluated the extent of neuroinflammation and
neuropathology at the later stages of infection. Our results showed that the inflammatory response
was more pronounced in the brain than in the lungs on days 5 and 6 after infection. Although both
our study and the previous studies infected mice via the intranasal route, the other studies used
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older (7- to 9-week-old) K18-hACE2 and a lower viral dose (104 PFU) and in one study, only
analyzed samples at 3 days after infection [84]. In our study, six-week-old K18- hACE2 mice
were infected with 105 PFU. However, unpublished data from our laboratory demonstrate that sixweek-old K18- hACE2 mice infected with a lower viral dose (103 PFU) also exhibit a similar
phenotype, suggesting that the brain is a major site of infection following infection by the
intranasal route regardless of the virus dose used. Additional studies are needed to clarify the
parameters that differentially affect tissue tropism, routes of virus dissemination, and mechanisms
of lung and brain injuries in K18-hACE2 mice following SARS-CoV-2 infection. Recent studies
have suggested that humans have a higher chance of developing a brain infection if they are
infected intranasally with a high dose of virus [109].

Alterations in smell and taste are features of COVID-19 disease in humans [10, 73].
Pathological analyses of human COVID-19 autopsy tissues detected the presence of SARS-CoV2 proteins in endothelial cells within the olfactory bulb [73, 75]. Our data indicate that SARSCoV-2 can productively infect cells within the nasal turbinate, eye and olfactory bulb in
intranasally infected K18- hACE2 mice. Virus infection of cells in these tissues in humans may
explain the loss of smell associated with some COVID-19 cases [73]. The detection of virus
replication in these tissues suggests that SARS-CoV-2 can access the brain by first infecting the
olfactory bulb and then spreading into the brain by infecting connecting brain neuron axons. This
hypothesis is consistent with previously published reports that neurotropic coronaviruses infect
olfactory neurons and are transmitted to the brain via axonal transportation [10, 95, 96, 110]. Many
viruses, such as HSV-1, Nipah virus, rabies virus, Hendra virus and influenza A virus, have also
been shown to enter the CNS via olfactory sensory neurons [111-114]. Another route by which a
virus can gain access to the brain is via the disruption of the blood-brain barrier (BBB). However,
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we could not detect any virus in the serum of the infected mice at any time after infection tested,
suggesting a limited role of BBB disruption in SARS-CoV-2 neuroinvasion. This finding is in
agreement with previously published studies that detected little or no virus in the blood of K18hACE2 mice after infection with SARS-CoV-1 or SARS-CoV-2 [81-84, 96, 105].
In summary, we found that intranasal Infection of K18-hACE2 mice by SARS-CoV-2 causes
severe neurological disease. Our data demonstrate that the CNS is the major target of SARS-CoV2 infection in K18-hACE2 mice under the conditions used, and that brain infection leads to
immune cell infiltration, inflammation and cell death.
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SARS-COV-2 INFECTS PRIMARY NEURONS FROM HUMAN ACE2
EXPRESSING MICE AND UPREGULATES GENES INVOLVED IN THE
INFLAMMATORY AND NECROPTOTIC PATHWAYS

Transgenic mice expressing human angiotensin-converting enzyme 2 under the cytokeratin
18 promoter (K18-hACE2) have been extensively used to investigate the pathogenesis and tissue
tropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.
Neuroinvasion and replication of SARS-CoV-2 within the central nervous system (CNS) of K18hACE2 mice is associated with increased mortality, although the mechanisms by which this occurs
remain unclear. In this study, we generated primary neuronal cultures from K18-hACE2 mice to
investigate the effects of a SARS-CoV-2 infection. We also evaluated the immunological response
to SARS-CoV-2 infection in the CNS of K18-hACE2 mice and mouse neuronal cultures. Our data
show that neuronal cultures obtained from K18-hACE2 mice are permissive to SARS-CoV-2
infection and support productive virus replication. SARS-CoV-2 infection upregulated the
expression of genes involved in innate immunity and inflammation, including IFN-α, ISG-15,
CXCL10, CCL2, IL-6 and TNF-α, in the neurons and mouse brains. In addition, we found that
SARS-CoV-2 infection of neurons and mouse brains activates the ZBP1/pMLKL-regulated
necroptosis pathway. Together, our data provide insights into the neuropathogenesis of SARSCoV-2 infection in K18-hACE2 mice.
4.1

Introduction
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome

coronavirus-2 (SARS-CoV-2) continues to be a global concern. In addition, several variants of
SARS-CoV-2 have been identified that may influence antibody treatment and vaccine efficiency
[8, 9, 27, 71]. Neurological complications, such as brain fog, loss of taste and smell, changed
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mental status and anosmia have been reported in some COVID-19 patients [10, 11, 17, 32, 115].
Studies have shown presence of meningitis, encephalitis, leukocytes infiltration and neuronal death
in COVID-19 patients [31, 32]. Evidence of SARS-CoV-2 neuroinvasion in COVID-19 patient
brain autopsies has been demonstrated and the olfactory mucosa has been suggested as a route of
entry [27, 28, 32, 109, 116]. Several studies have also reported that neurologic symptoms may
result from the exacerbated systemic pro-inflammatory responses without direct infection of the
brain cells [115, 116]. Angiotensin-converting enzyme 2 (ACE2), the entry receptor of SARSCoV-2, has recently been demonstrated to be present on neurons and glial cells of different brain
regions[10, 24-26, 78, 79].Studies using brain organoids derived from human pluripotent stem cell
(hPSC)-derived have shown the presence of virus in neuronal cells [29, 30, 117, 118].. In addition,
anti-ACE2 antibodies can inhibit the SARS-CoV-2 infection of neuronal cells[117] [19].
The K18-hACE2 mouse model is commonly used to study pathogenesis of SARS-CoV-2
infection and to test the efficacy of anti-viral compounds and vaccines. These mice express human
ACE2, the entry receptor of SARS-CoV-2 [81-84].We previously reported that infection of K18hACE2 mice with SARS-CoV-2 results in a lethal disease associated with viral neuroinvasion and
severe neuronal damage [119]. However, the molecular mechanism by which SARS-CoV-2
infection of neurons leads to acute encephalitis in K18-hACE2 mice remain unclear. The present
study was undertaken to i) investigate the permissiveness neurons to SARS-CoV-2 infection, and
ii) evaluate the immunological response to SARS-CoV-2 infection in the CNS of K18-hACE2
animals and mouse neuronal cultures. Our data show that neuronal cultures obtained from K18hACE2 mice are permissive to SARS-CoV-2 infection and support productive virus replication.
In response to infection, genes involved in the innate immune response, inflammation and cell
death were upregulated in the neurons. In addition, SARS-CoV-2 infection of mouse brains also
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resulted in increased expression of genes associated with the inflammatory and cell death
pathways.
4.2

Materials and Methods
4.2.1

Neuronal cultures and SARS-CoV-2 infection

Hemizygous K18-hACE2 mice and non-hACE2-carrier (NC) mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). One-day-old pups were obtained from established
breeding pairs of K18-hACE2 and NC mice as previously described [98, 120, 121]. The neurons
were plated for 24 hours onto poly-D-lysine-coated plates in serum Neurobasal A medium.
Neurons were then cultured in serum-free Neurobasal A medium containing B27 for seven days
to allow differentiation. The neurons isolated from each pup were plated separately and genotyped
to identify hACE2-expressing and NC neurons. Neuronal cultures were infected with SARS-CoV2 (USA-WA1/2020) or mock-infected at a multiplicity of infection of 0.1. At various time points
after infection, supernatants and cell lysates were collected[39, 122-124].
4.2.2

Animal infection experiments

The in vivo animal experiments with SARS-CoV-2 were conducted in an Animal Biosafety
Level 3 (ABSL-3) laboratory. Georgia State University Institutional Animal Care and Use
Committee approved the experimental protocol of this study (Protocol number A20044).
Hemizygous K18-hACE2 mice aged eight-weeks were inoculated with PBS or 104 PFU of SARSCoV-2 via the intranasal route [119, 124].. On various days after the infection, animals were
anesthetized, perfused with PBS and brain tissues were collected.
4.2.3

Quantification of the viral titers

The levels of infectious virus in cell culture supernatants and brain tissues were determined
by using plaque formation assay. Quantitative RT-PCR was used to measure intracellular viral
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RNA levels using SARS-CoV-2 N gene primers [39, 80]. Total RNA was extracted from cell
pellets and brain tissues using a Qiagen RNeasy Mini kit (Qiagen, Germantown, MD, USA). Viral
genome copies per ug of total RNA were calculated using a standard curve of known amount of
viral RNA [39, 99, 119].
4.2.4

Immunostaining

Neuronal cells were grown on coverslips in 12-well plates and infected with SARS-CoV2 or PBS at a MOI of 0.1 for 48 hours[123]. Cells were washed with PBS and fixed in 4%
paraformaldehyde for 1 hour at room temperature. The cells were permeabilized and incubated
with anti-MAP2 (Catalog # PA5-17646) and anti-dsRNA (MABE1134) antibodies overnight at 4
C (Thermo Fisher Scientific, Norcross, GA, USA). Next day, cells were incubated with Alexa
Fluor 546- or Alexa Fluor 488-conjugated secondary antibody for 1 hour at room temperature[119,
123, 125]. The Invitrogen EVOS™ M5000 Cell Imaging System. was used to capture the images.
4.2.5

Western blot analysis

Protein extracted from neuronal cultures and mouse brains were separated on SDS-PAGE
and transferred onto PVDF membranes. The membranes were incubated with primary antibodies
against ZBP1 (Cat #703166), pMLKL (Thermo Fisher Scientific, Norcross, GA, USA) and βactin. To visualize the protein bands, the membranes were incubated with secondary antibody
conjugated with IRDye 800 and IRDye 680 (Li-Cor Biosciences). The membranes were scanned
using the Odyssey infrared imager (Li-Cor Biosciences)[125, 126].
4.2.6

ELISA

ELISA was used to measure the protein levels of IL-6 (Invitrogen, Catalog # 50-246-676)
and IFN-β (PBL Assay Science, Catalog # 12405-1) and CXCL10 (Invitrogen, Catalog # 50-182-
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92) in the cell culture supernatants, according to the manufacturer’s instructions. The plates were
analyzed using a Victor 3 microtiter reader as previously described [80].
4.2.7

qRT-PCR

A Qiagen RNeasy Mini kit (Qiagen, Germantown, MD, USA) was used to extract total
RNA from cell pellets and brains. cDNA was synthesized from RNA using an iScript™ cDNA
Synthesis Kit (Bio-Rad). qRT-PCR was used to determine the expression levels of multiple host
genes [2].. The fold-change in infected samples compared to control samples was calculated after
normalizing to the housekeeping GAPDH gene [39, 119, 123, 124]. The primer sequences used
for qRT-PCR are listed in Table 1.

Table 2: Primer sequences used for qRT-PCR for gene expression.

Gene (Accession No.)

Primer Sequence (5'-3')

IL-1β (NM_000576)
Forward

AGCACCTTCTTTCCCTTCATC

Reverse

GGACCAGACATCACCAAGC

IL-6 (NM_000600)
Forward

CCAGGAGCCCAGCTATGAAC

Reverse

CCCAGGGAGAAGGCAACTG

CCL3 (NM_011337)
Forward

ATTCCACGCCAATTCATC

Reverse

ATTCAGTTCCAGGTCAGT

IFN-α (NM_010502)

36
Forward

CTCTGTGCTTTCCTGATG

Reverse

CTGAGGTTATGAGTCTGAG

TNF-α (NM_013693)
Forward

CCAGTCTGTATCCTTCTAA

Reverse

TCTTGTGTTTCTGAGTAGT

CCL2 (NM_011333)
Forward

TCACCTGCTGCTACTCATTCACCA

Reverse

TACAGCTTCTTTGGGACACCTGCT

ISG-15 (NM_015783)
Forward

AGAGCCACTGTTGGTTAT

Reverse

TTTCCTCGTTTACATTTCCA

Caspase 1 (NM_009807)
Forward

GGAAGCAATTTATCAACTCAGTG

Reverse

GCCTTGTCCATAGCAGTAATG

Caspase 3 (NM_009810)
Forward

ATCCTGAAATGGGCATAT

Reverse

CTTCCTTAGAAACACTATCC

Caspase 7 (NM_007611)
Forward

GTGACACCCATAAAGGAT

Reverse

ATGCCTGAATGAAGAAGA

Caspase 8 (NM_009812)
Forward

CTAGTTCTCTCAGTTGTCTTT

Reverse

GAGGTTTGCTACCGATTC
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ZBP1 (NM_021394)
Forward

GAAATAAGCACCTTCTGAG

Reverse

GAATTGGCAATGGAGATC

MLKL (NM_029005)
Forward

GGAACTTAGGCTATGGATA

Reverse

CGGCAGTATTTCATCTTT

4.2.8

Statistical Analysis

Unpaired student t-tests using GraphPad Prism 5.0 were used to calculate the p values.
Differences of p < 0.05 were considered significant.
4.3

Results
4.3.1

SARS-CoV-2 infection of primary mouse cortical neurons

Primary neuronal cultures were established from one-day-old K18-hACE2 (hACE2
neurons) and non-hACE2-carrier (NC neurons) pups and cultured for seven days to allow
differentiation to occur. The neuronal cultures were infected with SARS-CoV-2 at a multiplicity
of infection (MOI) of 0.1. Plaque assay, qRT-PCR and immunofluorescence were used to
determine the kinetics of SARS-CoV-2 replication at various time points after infection.
Productive SARS-CoV-2 replication, as indicated by the release of virions was detected at 24 hours
after infection of the hACE2 neurons. Viral titers peaked at 48 hours after infection (log 5–6
PFU/mL) followed by a slight decrease in the virus titers at 72 hours (Figure 1A). We next
measured intracellular viral RNA levels using qRT-PCR. High SARS-CoV-2 RNA levels were
detected in the hACE2 neurons at 48 and 72 hours after infection (log 6-7 genome copies/ug RNA).
Neurons derived from NC mice were relatively resistant to infection compared to the hACE2
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neurons. There was a slight increase in virus and RNA levels at 48 and 72 hours, suggesting limited
virus replication in these cells (Figure 1B). Immunofluorescence assay of SARS-CoV-2-infected
hACE2 neurons showed strong dsRNA staining. dsRNA was detected in both the neuronal bodies
and axons of the MAP2-positive cells at 48 hours after infection (Figure 1C). dsRNA detection is
considered as evidence of viral RNA replication. Approximately 40% of hACE2 neurons were
positive for dsRNA at 48 hours after infection. Overall, these findings indicate that neurons derived
from K18-hACE2 mice are permissive to SARS-CoV-2 infection and support productive virus
replication.

Figure 8: SARS-CoV-2 infection of mouse neuronal cultures. K18-hACE2 (hACE2
neurons) and non-hACE2-carrier (NC neurons) were prepared from one-day-old pups and cultured
for seven days for differentiation. (A) hACE2 (blue bars) and NC neurons (red bars) were infected
with SARS-CoV-2 at a MOI of 0.1. Virus infectivity titers in the supernatants were measured by
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plaque formation assay and are expressed as plaque forming units (PFU)/mL. (B) Intracellular
viral RNA copies were determined by qRT-PCR. The data are expressed as genome copies/ug of
RNA. Values are the mean ± SEM of three independent infection experiments conducted in
duplicate. Each data point represents an independent experiment. (C) hACE2 neurons grown
coverslips were fixed at 48 hours after infection and stained with anti-MAP2 (red), dsRNA (green)
and DAPI (blue) antibodies. In the bottom row of panels, the boxed areas from the first row are
expanded. The images shown are representative of three independent infection experiments. 20×
magnification.

4.3.2

Host immune responses in SARS-CoV-2-infected neurons and mouse brains

We next investigated the effect of SARS-CoV-2 infection on the mRNA expression of key
innate immune and inflammation genes in the neurons. Changes in gene expression levels in
hACE2 neurons infected with SARS-CoV-2 for 48 hours compared to mock-infected controls
were analyzed by qRT-PCR. Interferon stimulated gene (ISG)-15 mRNA expression increased by
>100-fold after SARS-CoV-2 infection (Figure 2A). The levels of interferon (IFN)-α and IFN-β
were elevated more than 10-fold. The mRNA levels of the chemokine pathway-associated genes,
chemokine (C-C motif) ligand-2 (CCL2) and chemokine (C-X-C motif) ligand-10 (CXCL10),
were upregulated by more than 50-fold in infected neuronal cultures (Figure 2B). Interleukin-6
(IL-6), IL-1β and tumor necrosis factor (TNF)-α mRNA expression levels were upregulated >10fold by a SARS-CoV-2 infection. CCL3 mRNA levels were also increased compared to the mockinfected controls (Figure 2B).
Next, we examined the mRNA levels of innate immune and inflammatory genes in the
brains of infected mice. K18-hACE2 mice infected with PBS or 104 PFU of SARS-CoV-2 via the
intranasal route [80].. The mice were sacrificed at days 1, 3 and 6 after infection, and the brains
were harvested. Plaque assay was conducted to determine infectious virus titers in the brain
homogenates. No infectious virus was detected in the brains on day one but virus infectivity titers
were very high at day 3 (log 3-4 PFU/gram of brain tissue) and day 6 after infection (log 7-8
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PFU/gram of brain tissue) [28]. IL-6 and TNF-α mRNA levels increased by >5-fold on day 3 after
SARS-CoV-2 infection (Figure 2C). By the sixth day after infection, IL-6 and TNF-mRNA levels
in the brain had increased by 300-fold (Figure 2C). There was also a 100-fold increase in the IL1β mRNA levels on day 6. The was a slight upregulation in the levels of IFN-α mRNA (Figure
2C). At day 6 after infection, expression levels of chemokines, including CXCL10 and CCL2 and
CCL-3 were elevated by more than 300-fold (Figure 2D).
As these pro-inflammatory cytokines are secreted proteins, their release in the culture
media of mock- and SARS-CoV-2 -infected hACE2 neurons was detected using ELISA. In
controls, basal levels of IL-6 and IFN-β in cell culture media were very low. On the other hand,
significant amounts of soluble IL-6 and IFN-β were detected in supernatant from infected cells at
48 hours after infection (Figure 3). Basal level of CXCL10 was relatively high, but it also increased
significantly after SARS-CoV-2 infection. These results indicate that SARS-CoV-2 infection
upregulates the expression of innate immune and inflammatory genes in neuron cultures and
mouse brains.
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Figure 9: Analysis of upregulation of the expression of immune genes involved in
innate immunity and inflammation in primary mouse neurons and mouse brains. (A and B)
hACE2 neurons were infected with SARS-CoV-2 or mock-infected at a MOI of 0.1. At 48 hours
after infection, cell pellets were collected, and total RNA was extracted. qRT-PCR was conducted
to determine the fold-change of (A) ISG15, IFN-β and IFN-α, and (B) CXCL10, CCL2, IL-6, IL1β, TNF-α and CCL3 mRNA levels. Data for each sample was normalized to the value for GAPDH
and expressed as the relative fold increase compared to mock-infected controls. Data represent the
mean ± SEM of three independent infection experiments conducted in duplicate. Each data point
represents an independent experiment. (C and D) Eight-week-old hemizygous K18-hACE2 mice
were infected with SARS-CoV-2 (104 PFU, n = 12) or PBS (Mock, n = 9). Brains were harvested
after extensive perfusion with PBS at days 1, 3 and 6 after infection and RNA was extracted. The
mRNA levels of (C) IL-6, IL-1β, TNF-α and IFNα, and (D) CXCL10, CCL2 and CCL3 were
determined by qRT-PCR. Each data point represents an individual mouse. Data represent the mean
± SEM.
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Figure 10: Protein levels of IL-6, IFN-β and CXCL10 in SARS-CoV-2 infected
neurons
Supernatant collected from hACE2 neurons infected with SARS-CoV-2 or mock-infected
for 48 hours was used to determine the levels of IL-6 and IFN-β and CXCL10 using ELISA. The
data expressed are the mean concentration (pg/ml) ± SEM of the amount of IL-6 and IFN-β and
CXCL10 secreted in the supernatant and is representative of three independent experiments. **p
< 0.001.
4.3.3

SARS-CoV-2 infection activates the ZBP1/MLKL pathway in neurons and
mouse brains

We examined the mRNA and protein levels of genes involved in cell death pathways in
neurons after SARS-CoV-2 infection. qRT-PCR was used to analyze the changes in the gene
mRNA levels. Key genes involved in the necroptotic pathway were highly upregulated in hACE2
neurons infected with SARS-CoV-2 for 48 hours. The levels of Z-DNA binding protein 1 (ZBP1)
and mixed lineage kinase domain-like (MLKL) mRNA were elevated ~50-fold after SARS-CoV2 infection. mRNA expression levels of caspase-8 and receptor-interacting kinase-3 (RIPK3) were
upregulated >10-fold after infection (Figure 4A). Pyroptotic gene caspase-1 was upregulated by
10-fold while the apoptotic genes, caspase-3 and caspase-7 showed no significant increase after
SARS-CoV-2 infection (Figure 4B). To verify the activation of the necroptotic pathway, protein
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levels of ZBP1 and phosphorylated MLKL (pMLKL) were measured by immunoblotting. The
levels of ZBP1 increased at 24 and 48 hours after infection. We detected a modest increase in the
protein levels of pMLKL at 24 and 48 hours after infection. However, there was a significant
increase in the levels of pMLKL protein at 72 hours (Figure 4C).
Next, we evaluated the activation of the necroptotic pathway in mouse brains infected with
SARS-CoV-2. mRNA expressions of ZBP1 and MLKL increased gradually in the brains from
days 1 to 6 after SARS-CoV-2 infection. By the sixth day after infection, IL-6 and TNF-mRNA
levels were upregulated ~50-fold in the brains (Figure 4D). The mRNA levels of RIPK3, RIPK1,
Caspase 8 and Caspase 1 were also elevated by day 6 (Figure 4D and E). However, there was no
significant increase in the levels of caspase-3 and caspase-7 mRNA in infected brains. Western
blot data showed an increase in the protein levels of ZBP1 and pMLKL in the infected brains in a
time-dependent manner (Figure 4F). The increase in the mRNA and protein levels of ZBP1 and
MLKL correlate with the increase in the infectious virus titers in the brains[119]. Together, these
results indicate that a SARS-CoV-2 infection in neurons and mouse brains activates the
ZBP1/MLKL-regulated necroptosis pathway.
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Figure 11: mRNA and protein levels of genes involved in cell death pathways in
primary mouse neurons and mouse brains. (A and B) hACE2 neurons were infected with
SARS-CoV-2 or mock-infected at a MOI of 0.1. At 48 hours after infection, cell pellets were
collected, and total RNA was extracted. qRT-PCR was conducted to determine the fold-change in
(A) ZBP1, MLKL, RIPK3 and RIPK1, and (B) Caspase 8, Caspase 1, Caspase 7 and Caspase 8
mRNA levels. Data for each sample was normalized to the value for GAPDH and expressed as the
relative fold increase compared to mock-infected controls. Data represent the mean ± SEM of three
independent infection experiments conducted in duplicate. Each data point represents an
independent experiment. (C) hACE2 neurons were infected with SARS-CoV-2 or mock-infected
at a MOI of 0.1. At 24, 48 and 72 hours, cell pellets were collected, and total protein was extracted.
Protein was blotted with ZBP1, pMLKL or β-actin antibodies. Data are representative of three
independent experiments. (D and E) K18-hACE2 mice were inoculated with SARS-CoV-2 or PBS
via the intranasal route. Brains were harvested after extensive perfusion at days 1, 3 and 6 after
infection and RNA was extracted. qRT-PCR was used to determine the mRNA levels of (D) ZBP1,
MLKL, RIPK3 and RIPK1, and (E) Caspase 8, Caspase 1, Caspase 7 and Caspase 8. After
normalizing individual sample to GAPDH level, the fold change in infected tissues compared to
mock-infected controls was determined. Each data point represents an individual mouse (n = 4).
Values are the mean ± SEM. (F) Protein extracted from mock- and SARS-CoV-2-infected brain
tissues were blotted with ZBP1, pMLKL or β-actin antibodies. Data are representative of four mice
per time point.
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4.4

Discussion
In this study, we show that SARS-CoV-2 establishes a productive infection in neuronal

cultures obtained from hACE2-expressing mice. In response to infection, the expression of innate
immune and inflammatory genes was upregulated in the neurons as well as in mouse brains. In
addition, we found that SARS-CoV-2 infection of neurons and mouse brains upregulated genes
involved in the necroptotic pathway (ZBP1, MLKL RIPK3 and caspase-8), suggesting that
necroptosis may play a role in the pathogenesis of SARS-CoV-2 infection in the CNS.
It is known that some animal (mouse hepatitis virus) and human (HCoV-OC43)
coronaviruses productively infect neuronal cells [80, 127]. SARS-CoV-2 infection has been
detected in the brains of some COVID-19 patients [27, 28, 32, 109, 116]. SARS-CoV-2 has also
been shown to replicate and induce cell death in human neural progenitor cells and brain organoids
[29, 30, 117, 118, 128]. Transgenic K18-hACE2 mice represent a lethal model of SARS-CoV-2
infection [80-84]. Neuroinvasion and replication of SARS-CoV-2 within the CNS is associated
with mortality in these mice. In the present study, we show that neurons derived from one-day-old
K18-hACE2 mice are permissive to SARS-CoV-2 infection and support productive virus
replication. dsRNA was detected in the neuronal bodies and axons infected with SARS-CoV-2. In
comparison, virus replication was limited in the non-hACE2-expressing mouse neurons.
A cytokine storm is one of the pathological hallmarks of severe outcomes resulting from
SARS-CoV-2 infection [129, 130]. Several studies have reported that increased TNF-α and IL-6
levels correlate with severe disease outcomes [131, 132]. In the present study, we show that SARSCoV-2 infection in K18-hACE2 mouse brains is also characterized by upregulation of innate
immune and inflammatory genes, including TNF-α and IL-6 [119]. Similarly, a significant
increase in the expression of IL-6, TNF-α, CXCL10 and CCL2 was observed in SARS-CoV-2-
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infected neuron cultures. These inflammatory genes may activate downstream cell death signaling
pathways in the neurons, leading to neuronal death, and/or stimulate glial cells, exacerbating
neuroinflammation [132-134]. TNF-α has been reported as a potent inducer of neuronal injury in
several neurodegenerative diseases, such as cerebral ischemia, spinal cord injury, multiple
sclerosis and viral infections including HIV-associated dementia [33,36]. CXCL10 and CCL2 are
important chemokines involved in the infiltration of leukocytes into the CNS after virus infection
[134].
ZBP1 is one of the cytoplasmic sensors that regulate cell death and inflammation [122,
135]. ZBP1 initiates RHIM-dependent activation of RIPK3-dependent necroptosis during virus
infections. Necroptosis is an inflammatory cell death caused by RIPK3 phosphorylation, which
activates the pseudo-kinase MLKL, which oligomerizes and ruptures the plasma membrane,
resulting in cell death Necroptosis can eradicate virus-infected cells and activate innate and
adaptive immunity to limit virus replication. This process can also trigger the release of
inflammatory cytokines and damage-associated molecular patterns, resulting in robust
inflammation [135, 136]. In the present study, we found significant upregulation of the necroptotic
genes, ZBP1, MLKL and RIPK3, in neuronal cells and mouse brains after SARS-CoV-2 infection.
Previous studies have demonstrated that infection with beta coronaviruses can induce necroptosis
in certain cell types. Human coronavirus, HCoV-OC43, induces necroptosis in human neural cells
[127] and mouse hepatitis virus infection induces necroptosis in murine bone-marrow-derived
macrophages by phosphorylation of MLKL [137]. We previously reported that ZBP1 restricts
replication of West Nile virus and Zika virus in primary mouse cortical neurons[98]Future studies
are warranted to understand the role of ZBP1 in SARS-CoV-2 pathogenesis.
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Together, our results demonstrate that SARS-CoV-2 robustly replicates in neuronal
cultures obtained from K18-hACE2 mice. Like the SARS-CoV-2-infected K18-hACE2 mouse
brains, virus infection of neuronal cultures induces up-regulation of genes involved in the innate
immune response, inflammation and cell death.
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5

THE GLOBAL IMMUNE RESPONSE OF SARS-COV-2 INFECTION IN THE
MOUSE BRAIN

5.1

Introduction
Since the first outbreak in China in 2019, coronavirus disease 2019 (COVID-19) has spread

rapidly and globally with a mortality rate of 2% resulting in the ongoing pandemic. The lack of
highly efficacious antiviral drugs that can manage this ongoing global emergency gives urgency
to establishing a comprehensive understanding of the molecular pathogenesis of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Typical clinical presentation of COVID-19
can be characterized by upper and lower respiratory tract infections that are often associated with
fever and cough. Although most infections remain mild or asymptomatic, some patients experience
more severe disease and develop systemic inflammation, tissue damage, acute respiratory distress
syndrome, thromboembolic complications, cardiac injury, and/or cytokine storm [41].
Furthermore, SARS-CoV-2 infection is also associated with a wide variety of neurological
manifestations, such as headache, loss of taste and smell, ataxia, meningitis, cognitive dysfunction,
memory loss, seizures and impaired consciousness, as well as long-term neurological problems in
more than 30% of adults [27, 31]. However, the mechanism by which SARS-CoV-2 infection
causes neurological diseases remains unclear.
A better understanding of the global gene changes underlying the multi-step progression
of pathogenicity during infection could help develop potential therapeutic strategies for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neuroinflammation is a prominent
neuropathological signature in many neurodegenerative disorders, including Alzheimer's disease,
Parkinson's disease, Frontal Temporal Dementia, Amyotrophic Lateral Sclerosis, and prion
diseases. Using a Nanostring Neuroinflammation panel, we looked at the gene expression in the
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brains of K18-hACE 2 mice on days 1, 3, and 6 after SARS-CoV-2 infection. This panel examines
several critical processes and pathways to present a comprehensive picture of the immunological
and inflammatory responses in the nervous system. Assessment of neurotransmission, innate
immunity, inflammation, and cell death pathways are all important areas of neuropathology study.
Without the need for enzymatic target amplification, the nCounter technology allows for highthroughput, sensitive, quantitative, and repeatable gene expression analysis. Our data indicate that
the SARS-CoV-2 infection caused changes in multiple mRNAs in the brain.
We previously showed that SARS-CoV-2 intranasal infection of K18-hACE2 mice
resulted in brain encephalitis characterized by secretion of cytokines and chemokines, leukocyte
infiltration, hemorrhage, and neuronal cell death [119]. In the follow up study, we demonstrate
that neuronal cultures obtained from K18-hACE2 mice are permissive to SARS-CoV-2 infection
and support productive virus replication. Furthermore, SARS-CoV-2 infection upregulated the
expression of genes involved in antiviral immunity and inflammation in the brain [138].
Furthermore, we identified several significantly dysregulated and functionally relevant
genes associated with neuroinflammation during SARS-CoV-2 infection that are of value for
further studies.
5.2

Materials and Methods
5.2.1

SARS-CoV-2 Infection in Mice

As previously described, SARS-CoV-2 (USA-WA1/2020), was isolated from an
oropharyngeal swab from a patient in Washington, USA (BEI NR-52281)[97]. Virus titration was
performed using VeroE6 cells to further infection as previously described [80, 97]. Hemizygous
K18-hACE2 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). To infect mice
with SARS-CoV-2, we performed all the animal experiments in the Animal Biosafety Level 3

50
laboratory (ABSL3) at Georgia State University (GSU) following the protocol A20044 that was
accepted by the GSU Institutional Animal Care and Use Committee [80].
5.2.2

RNA Extraction and Evaluation

For RNA extraction, 6-week-old K18-hACE2 mice were intranasally inoculated with 105
PFU of SARS-CoV-2 (USA-WA1/2020) in ABSL3, whereas mock control group was inoculated
with equivalent amounts of PBS [80]. Approximately similar numbers of male and female mice
were used. During experiments, mice were checked for body weight, appetite, activity, and
neurological signs every 2 days following SARS-CoV-2 infection. On days 1-, 3-, and 6- after
inoculation, the mice were euthanized to limit suffering when met the human endpoint. The mockor SARS-CoV-2-infected mice were anesthetized using isoflurane and perfused with PBS and
RNA was collected from the brain.
RNeasy MiniKit (Qiagen, Hilden, Germany) was used to isolate total RNA from the brain
tissues by using the manufacturer’s instructions [139]. To measure the purity and quantity of total
RNA, Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) and NanoDrop
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) were used and the following
criteria: wavelength absorbance ratio A260/280 ~2.0, and A260/230 ~2.0), the percentage of RNA
fragments ≥300 nucleotides DV300 ≥ 50%, or integrity RIN > 4.
5.2.3

NanoString nCounter® Gene Expression

A commercially available NanoString nCounter® Mouse Neuroinflammation Panel to
count 770 immune-related genes (NanoString, Cat: XT-CSO-MIP1-12) were used following the
NanoString guidelines. A set of housekeeping genes were used. for normalization for gene
expression by using the nSolver Analysis Software (NanoString) as previously described [120].
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5.2.4

Gene Ontology (GO) and pathway enrichment analysis using Kyoto
Encyclopedia of Genes and Genomes (KEGG)

GO (https://david.ncifcrf.gov/) and KEGG (www.genome.jp/kegg/pathway.html) pathway
analysis was conducted to identify DEGs at the biologically functional level [140]. Among the GO
classification, three categories of biological process, cellular component, molecular function, and
the number of involved genes were represented.
5.2.5

Ingenuity Pathway Analysis (IPA)

NanoString data were analyzed using IPA (QIAGEN, Redwood City, USA) as described
previously [120, 134, 141]. Briefly, graphical abstracts, comparative analysis, and individual
analysis were analyzed using the identified list of DEGs by NanoString and IPA Knowledge Base
as described previously. The Ingenuity Knowledge Base is the largest database of manually
curated and experimentally validated physical, transcriptional, and enzymatic molecular
interactions. Statistical comparisons between pathways and network data, p values (Fisher’s exact
test), and activation z-score, were calculated by IPA. p < 0.05 is considered significant.
5.3

Results
5.3.1

Identification of differentially expressed upregulated and downregulated genes
in mouse brain

Using cutting-edge nCounter technology, the distribution of mRNA in K18-hACE 2 mice
brain infected with SARS-CoV-2 was examined. Six genes were found to be downregulated on
day 1 out of over 800 genes analyzed. On day 3, 14 genes were downregulated, and 6 were
upregulated. On day 6, 89 genes were downregulated, whereas 104 were upregulated. The highest
number of genes were either up or downregulated on day 6, with three genes being downregulated
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at all three-time points and five genes being downregulated on both days 3 and 6. 6 genes were
identified to be elevated on both days 3 and 6.

Figure 12: Diagram of differentially expressed genes on days 1, 3, and 6 after infection
with SARS-CoV-2. (A) The number of up (red) and down (blue) regulated genes in each group.
(B) Venn diagrams depict the number of genes differentially expressed in the brain on different
days after infection. (C) RT-PCR data for N gene showing viral load in the brain post-infection
with SARS-CoV-2.

5.3.2

Analysis of Cell death pathway associated genes expression

Neurologic symptoms may result from enhanced systemic pro-inflammatory reactions
without a direct infection of brain cells. Our data indicate that SARS-CoV-2 infection increased
the expression of genes implicated in innate immunity, inflammation, and cell death pathways
such as apoptosis, necroptosis, and NLR signaling. Several genes in NLR signaling pathways were
upregulated at day 6 with 3 downregulated genes.
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Figure 13: Heat map showing the two-fold change in cell death-associated genes.

Genes of cell death pathways are upregulated, including apoptosis and necroptosis
pathways at day 6 brain post-SARS-CoV-2 infection.
The inflammasome's activation is a crucial step in the inflammatory immune response that
leads to pyroptotic cell death. Members of the NLR family are inflammasome-initiating sensors
[75, 142]. TLR signaling, which upregulates NLPR3 and pro-IL-1 gene expression, is required for
Nlrp3 inflammasome activation in macrophages. Signals, which culminate in the activation of NFkB, carefully govern this process [143]. Furthermore, type I IFN signaling through STAT1 reduce
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the activity of the Nlrp3 inflammasome, which causes caspase-1 to process the IL1-beta precursor
in response to a wide range of intracellular PAMPs [134].
5.3.3

Analysis of genes associated with major Inflammatory pathways

Most of the genes of NF-kB, TLR, and TNF signaling pathways were upregulated on day
6, whereas only a few were downregulated on days 1, 3, and 6. In JAK/STAT pathways, the genes
were all upregulated in the day 6 brain. Cytokines and receptor interaction genes were highly
upregulated in the mouse brain after SARS-CoV-2 infection at day 6, with only two genes in the
pathways that were downregulated on days 1, 3, and 6. Major genes that play a role in COVID-19
infection were upregulated, with only three genes down-regulated at day 6 post-SARS-CoV-2
infection.

Figure 14: Heat map showing the two-fold change in inflammatory and cytokines and
chemokines gene expression.
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5.3.4

Pathway enrichment analysis using Kyoto Encyclopedia of Genes and Genomes
(KEGG)

The enrichment factor is calculated by dividing the number of DEGs by the total number
of genes in each enrichment pathway. Our data indicate that the genes involved in
cytokine/chemokine upregulation, inflammatory pathways, and leading programmed cell death
interact in the brain of SARS-CoV-2 infected mice, leading to the severity of the brain infection.

Table 3: Top 20 up and down DEGs in D1, D3, and D6

The above table shows the top 20 upregulated and downregulated DEGs on days 1, 3, and
6 mice brains after infection with SARS-CoV-2. Genes associated with inflammatory response,
cytokine and chemokine pathways, and cell death pathways were upregulated.
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Table 4: KEGG pathway enrichment analysis of DEGs in the SARS-CoV-2 infected
mouse brain.

5.4

Discussion

Previously, we have shown that genes and proteins of innate immunity and inflammatory
pathways were upregulated in neurons and mice brain in response to SARS-CoV-2 infection.
Furthermore, we discovered that SARS-CoV-2 infection of neurons and mouse brains upregulated
genes such as ZBP1, MLKL, RIPK3, and caspase-8, which are involved in the necroptotic
pathways implying that necroptosis may play a role in SARS-CoV-2 infection pathogenesis in the
CNS [123].
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Cytokine storm is involved in the pathogenesis of severe COVID-19 cases. The levels of many
cytokines and chemokines have been found to be increased after SARS-CoV-2 infection[27, 31].
Our Nanostring data show increased expression of several genes, including the innate immune
system and inflammatory genes such as TNF, IL-1 beta, CCL2, CCL3, CXCL10, and TLR. These
genes were also upregulated in the neuron cells of human ACE-2 expressing transgenic mice after
infection [123]. These inflammatory genes may cause neuronal death and exacerbation of
neuroinflammation in the brain by activating downstream cell-death signaling pathways. TNF is
known to be a potent inducer of neuronal injury in a variety of neurodegenerative illnesses,
including cerebral ischemia, spinal cord injury, multiple sclerosis, and viral infections, such as
HIV-associated dementia. CXCL10 and CCL2 are key chemokines involved in leukocyte
infiltration into the CNS following viral infection [39, 119, 138].
At both days 3 and 6, we discovered that ZBP1, CCL2, and CXCL10 were three genes that were
consistently elevated. ZBP1 is a crucial innate sensor that detects and binds Z-RNA structures
produced by various viruses, including herpesvirus, orthomyxovirus, and flavivirus, and causes
various forms of cell death [139]. ZBP1 is a key activator of necroptosis, a programmed cell death
process in response to death-inducing TNF-alpha family members. ZBP1 interacts with and
promotes the RIPK3 kinase, which phosphorylates and activates MLKL, causing programmed
necrosis to occur. We found highly upregulated ZBP1 expression in the brain of infected mice on
day 6, indicating ZBP1-dependent necroptosis in the mouse brain. Infection with beta
coronaviruses has been shown to cause necroptosis in some cell types in previous research.
Necroptosis is induced in human neural cells by the human coronavirus HCoV-OC43.
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To summarize, the nanostring data corresponds to the mRNA and protein levels of genes
implicated in necroptosis and inflammation reported in primary neurons isolated from K18-hACE2 animals, as previously demonstrated.
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6

PATHOGENESIS OF A SARS-COV-2 INFECTION IN THE AGED MICE

The aged population is at increased risk of severe illness from Coronavirus disease 2019 (COVID19). Because age is a risk factor for COVID-19-related morbidity and death in humans, we
evaluated the course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
infection in younger adults and older BALB/c mice. In this study, BALB/c mice aged six and
twenty months were injected intranasally with 105 Plague Forming Units (PFU) of SARS-CoV-2
mouse adapted (MA10) virus. The survival rate, weight loss, viral load, cytokine and chemokine
levels, and lung pathology were used to correlate disease severity and pathogenic index. Our data
show that the MA10 virus-infected and replicated in both younger and older BALB/c mice. On
day 3 post-infection, the mice lost a significant amount of body weight and reached the human
endpoint. On day 3, plaque assay and qRT-PCR revealed a considerably high virus titer in the
lungs and elevated inflammatory cytokines and chemokines. Gross pathology with multifocal lung
lesions was seen in 20-months-old, infected mice, and an H&E section of the lungs revealed
extensive leucocyte infiltrations. Interestingly, IFN- α expression was found to be upregulated in
younger adults compared to older mice at day 3 post-infection. Our data show that older BALB/c
mice facilitated rapid MA10 viral replication in an age-dependent manner, as evidenced by rapid
body weight loss, gross and microscopic pulmonary pathology, and mRNA levels of inflammatory
cytokines and chemokines. Overall, our results suggest that elderly hosts have a higher risk of
infection.
6.1

Introduction

Due to immunological changes that occur as people age, they are more susceptible to numerous
illnesses. Immunosenescence refers to a set of alterations that include decreased innate and
adaptive immune responses and increased production of inflammatory cytokines. The United
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States and Brazil are among the countries with the most cases and deaths due to the Covid-19
pandemic. COVID-19 is responsible for about 51% of SARS cases in Brazil, with 73 percent of
deaths occurring in those over 60 years of age [144]. It has been discovered that older adults have
a more severe form of the disease and constitute the leading COVID-19 risk group [145]. SARSCoV-2 infection in experimental models confirmed this observation, with infected old Syrian
hamsters developing alveolar and perivascular edema [146]. SARS-CoV-1 and MERS have both
been linked to a higher severity in older people [147].
Moreover, Obesity, hypertension, and metabolic disorders are also risk factors for COVID-19
[148]. SARS-CoV-2 virus causes worse outcomes and higher mortality in older adults and those
with comorbidities like hypertension, cardiovascular disease, diabetes, chronic respiratory disease,
and chronic kidney disease (CKD). These conditions affect many older Americans, putting them
at risk of severe infection. Many people with hypertension, diabetes, and CKD are also given
Angiotensin-Converting Enzyme (ACE) inhibitors and angiotensin II receptor blockers. The
ACE2 receptor, which the virus uses to enter host cells, is upregulated by these drugs (5).
Animal models are essential for the development and validation of prophylactics and treatments,
as well as the identification of the mechanisms underlying COVID-19 pathogenesis. Because the
elderly is more prone to severe SARS-CoV-2 infection, older mice may also be more sensitive
than younger mice. In this study, we evaluated the pathogenicity of the SARS-CoV-2 in younger
adults (six months) and aged (Twenty months) old BALB/c mice. Our data show that intranasal
inoculation of SARS-CoV-2 in the older BALB/c mice resulted in severe disease, as evident by
rapid loss of body weight, gross and microscopic pathology of lungs, as well as elevated mRNA
levels of inflammatory cytokines and chemokines.

61
It is thought that cytokine storm in the lungs is one of the immunological components implicated
in COVID-19 pathophysiology in the elderly. Although it has been suggested that alveolar
macrophages from older people have an anti-inflammatory profile, they can develop higher and
uncontrolled responses of cellular activation and cytokine production in response to a pathogen
insult, as well as a lower ability to control tissue damage due to infection, putting the lungs in a
debilitated state [149-151]. Indeed, levels of complement and surfactant proteins, as well as proinflammatory cytokines, are higher in the lungs of older people at baseline [150, 151].
Surprisingly, a cytokine storm occurs in half of all fatal COVID-19 cases, with 82 percent of those
over 60 years of age [152]. This situation of immune failure and its link with disease development
in the elderly has been extensively researched, particularly in potentially lethal infections, such as
influenza and, more recently, COVID-19. Understanding the infection dynamics in this scenario
can benefit a better comprehension of these mechanisms.

6.2

Materials and Methods
6.2.1

Animal Infection Experiments

BALB/c mice were obtained from the Jackson laboratory, USA. All the animal
experiments were conducted in a certified Animal Biosafety Level 3 (ABSL-3) laboratory at
Georgia State University (GSU). The protocol was approved by the GSU Institutional Animal Care
and Use Committee (Protocol number A20044). Six- and 20- months old BALB/c mice were
inoculated intranasally with PBS (mock) or 105 plaque-forming units (PFU) of MA10 as described
previously[119]. Animals were weighed, and their appetite, activity, breathing, and neurological
signs were accessed twice daily. In an independent experiment, mice were inoculated with PBS
(mock) or SARS-CoV-2 variants intranasally, and on day 3 after infection, animals were
anesthetized using isoflurane and perfused with cold PBS. The lungs and other tissues were
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collected and flash-frozen in 2-methyl butane (Sigma, St. Louis, MO, USA) for further analysis as
described below [125, 153, 154].
6.2.2

Quantification of the virus load

Tissues harvested from mock and virus-inoculated animals were weighed and
homogenized in a bullet blender (Next Advance, Averill Park, NY, USA) using stainless steel
beads, followed by centrifugation and titration. Virus titers in tissue homogenates were measured
by plaque assay using Vero E6 cells. To titer the infectious virus, tissue homogenates were 10-fold
serially diluted with DMEM and applied to monolayered Vero E6 cells for 1 hour. After
inoculation, cells were washed once before overlaid with 1% low-melting agarose. Cells were
further incubated for 72 hours and stained with neutral red to visualize plaque formation.
6.2.3

Quantitative real time-polymerase chain reaction (qRT-PCR)

Total RNA was extracted from tissues using a Qiagen RNeasy Mini kit (Qiagen,
Germantown, MD, USA). One microgram (ug) of RNA was reverse transcribed to make cDNA
using iScript TM cDNA Synthesis Kit (Bio-Rad, Des Plaines, IL, USA) [39, 80]. qRT-PCR was
conducted on tissue lysates from mock and MA10 virus-infected samples to determine virus N
gene expression and expression of various pro-inflammatory cytokines and chemokine. The
mRNA levels of multiple host genes were determined using qRT-PCR, and the fold change in
infected samples compared to controls was calculated after normalizing to the GAPDH gene.
Primer sequences are listed in Table 1.
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Table 5: Primer sequences used for Quantitative real time-polymerase chain
reaction.

IL-6 (NM_000600)
Forward

CCAGGAGCCCAGCTATGAAC

Reverse

CCCAGGGAGAAGGCAACTG

TNF-α (NM_013693)
Forward

CCAGTCTGTATCCTTCTAA

Reverse

TCTTGTGTTTCTGAGTAGT

CCL2 (NM_011333)
Forward

TCACCTGCTGCTACTCATTCACCA

Reverse

TACAGCTTCTTTGGGACACCTGCT

IFN-α (NM_010502)

6.2.4

Forward

CTCTGTGCTTTCCTGATG

Reverse

CTGAGGTTATGAGTCTGAG

Histopathological Analysis

Lung sections were stained with hematoxylin and eosin (H&E) for histopathological
evaluation[104, 126]. Additionally, tissue sections were incubated with anti-SARS-CoV-2
nucleocapsid antibody (Thermo Fisher Scientific, Norcross, GA, USA) overnight at 4 °C, followed
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by incubation with Alexa Fluor 555-conjugated secondary antibody (Invitrogen) for 1 hour at room
temperature. Images were acquired using the Invitrogen™ EVOS™ M500 Cell Imaging System
(Thermo Fisher Scientific, Norcross, GA, USA).
6.2.5

Statistical Analysis

Mann–Whitney tests and unpaired student t-tests using GraphPad Prism 5.0 were used to
calculate the p values of the difference between viral titers and immune responses, respectively.
Differences of p < 0.05 were considered significant.
6.3

Results
6.3.1

MA10 virus replication in younger adult and aged BALB/c mice

The six months old younger adult and 20 months old aged BALB/c mice were infected
intranasally with PBS (mock, n=10 mice) or 105 PFU of MA10 in PBS (n=10 mice) to evaluate
the pathogenicity of the virus. Mice were monitored for clinical signs and changes in body weight.
The mock-infected mice remained healthy throughout the observation period. Infected mice
experienced significant weight loss by day 3 pi. We observed approximately 18-20% loss in body
weight of infected mice of both age groups but not mock (Figure 1A). All the infected animals
were euthanized at day 3 because they reached the humane endpoint. Lungs of 20- months old
mice had gross lesions with focal or multifocal discoloration in the lung lobes compared to younger
adults or mock-infected mice (Figure 1B). In 20-month-old mice, gross pathological examinations
indicated macroscopically evident discoloration of lung tissues on day 3 pi.
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Figure 15: Analysis of body weight in BALB/c mice following intranasal infection with
MA10 105 PFU. (A) 6- and 20-months old mice were inoculated intranasally with PBS or 105
PFU of MA10. (B) In 20-month-old mice, gross pathological examinations indicated
macroscopically evident lesions (black arrow) and discoloration (red arrow) of lung tissues on day
3 pi.
6.3.2

Viral load in the lungs of BALB/c mice after SARS-CoV-2 infection

Six months and 20 months old BALB/c mice were infected intranasally with PBS (mock,
n= 10) or log5 PFU of MA10 in PBS (n=10), and groups of 5 mice were used to measure the viral
loads in the lungs at day 3 pi. We used plaque assay and qRT-PCR to quantify viral titers in the
lungs of infected mice. Our data show that the MA10 was able to infect and replicate in both the
age group, younger adult and older mice. High virus titer levels were observed in the lungs at day
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3. The virus titer was approximately log 7 in 20 months old whereas the six months old virus titer
was one log value less and it was log 6. Six months old younger adults and 20 months old-aged
mice had significantly higher viral titers; however, the virus titer in the older mice was comparably
higher.

Figure 16: Replication of MA10 virus in the lungs of the infected mice. (A) 6- and 20months old mice were inoculated intranasally with log5 PFU of MA10. A Group of 4-5 mice was
euthanized on Day 3 after infection, and lung tissues were collected. Virus titers were analyzed in
the lungs by (A) plaque assay and (B) qRT-PCR.

6.3.3

Cytokines and chemokines expression levels in the MA10 virus-infected mice
lungs

Interferons (IFNs) are the body's first line of antiviral defense, inhibiting virus replication
at several levels by triggering the expression of hundreds of IFN-stimulated genes, several of
which have antiviral properties. IFN signaling interacts with pathways that control apoptosis,
inflammation, and cellular stress response programs to establish the cell's overall antiviral state
[80, 155]. The level of IFN- α mRNA expression in day 3 lungs was investigated. When compared
to the mock group, IFN- α expression was ∼ 25 times higher in 6-month-old younger adults. In
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comparison to the mock, there was only a negligible increase in IFN- α expression in 20-monthold mice.
Next the mRNA levels of inflammatory cytokines and cytokines in the day 3 lungs were
examined. MA10 infection caused ∼ 50-fold increase in IL-6 gene expression in the lungs of 6months old mice, but an ∼ 80 fold increase in the lungs of 20-month-old mice. TNF- α levels were
somewhat elevated ∼5 fold in the lungs of younger adults and ∼7 fold in the lungs of older mice
when compared to mock. When compared to mock, CCL-2 mRNA expression was enhanced
approximately 50-fold in younger mice and around 120-fold in older mice. It's worth noting that
relative IFN- α levels were higher in younger adults aged 6 months compared to mice aged 20
months. On contrary, the expression of inflammatory genes, IL-6, TNF- α, and CCL-2 was
increased in 20-month-old mice than in 6-month-old mice. When compared to 20-month-old mice,
our findings suggest that younger mice produced a better IFN-α response. This finding is consistent
with prior research that found IFN signaling was critical in SARS-CoV-2 MA viral replication
attenuation [156].
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Figure 17: Analysis of cytokine and chemokine levels in the lungs of MA10-infected
mice were determined by qRT-PCR. The mRNA levels of inflammatory cytokines and
chemokine, IL-6, TNF- α, and CCL-2 were upregulated in 20 months old compared to 6 months
old mice. Whereas IFN-α gene expression was increased in 6 months old compared to 20 months
old. The fold change in the infected tissues compared to the corresponding mock-infected controls
was calculated after normalizing individual samples to GAPDH levels. Values are the mean ±
SEM (n = 4–5 mice per group). *, p < 0.05; **, p < 0.001.

6.3.4

MA10 infection-induced pathological features in the infected mice lungs

We analyzed gross and histopathological changes in the infected mice lungs. We analyzed
the lung sections from 20 months old, infected mice for infiltration of immune cells and antigen
distribution. The H&E staining of lung sections from 20 months old, infected mice demonstrated
abundant leukocyte infiltration in alveolar spaces, interstitial thickening, and extravasated blood
in day 3 pi.
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Figure 18: Histopathological analysis of MA10 infected lungs in older mice.
Hematoxylin and eosin (H&E) staining of lung sections from mock- and MA10 infected
mice on day 3 after infection. Lesions with significant leukocyte infiltration, hemorrhages, and
interstitial thickening were seen in lung sections of infected mice. The photomicrographs shown
are representative of the images obtained from five animals.
Lung sections from mock and infected mice were also stained for SARS-CoV-2
nucleocapsid protein. The immunofluorescence images show the presence of SARS-CoV-2 N
protein (red) in the infected mice. Nuclei are stained with DAPI (blue). This shows the virus
replication in the lungs at D3.
CD45 is a major transmembrane glycoprotein expressed in all leucocytes. It has been
established that the expression of CD45 is essential for activating T cells via the T cell receptor
(TCR). Evidence of leucocyte infiltration was confirmed by immunofluorescence staining analysis
of the CD45 antigen, which revealed many CD45 positive cells in these lungs.
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Figure 19: Detection of infected cells in the lungs of MA10-infected mice. Lung sections
from mock- and MA10-infected mice (day 3 after infection) were stained for (A) SARS-CoV-2
nucleocapsid protein and (B) leucocyte marker CD45. Representative immunostaining images
show SARS-CoV-2 nucleocapsid protein (red) in the MA10-infected mice. Nuclei are stained with
DAPI (blue). The photomicrographs shown are representative of the images obtained from five
animals.

6.4

Discussion

Aging affects many characteristics of innate and adaptive immune cells, impairing or
compromising their function and response. Several variables can also disrupt intracellular
homeostasis as people age, increasing the production of inflammatory cytokines and chemokines
[144]. To investigate the pathogenesis of SARS-CoV-2 and explore possible antiviral treatments
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and vaccines, appropriate animal models are required. An ideal animal model would be able to
emulate viral replication and clinical consequences in COVID-19 patients [157]. Although several
SARS-CoV-2 mouse models have been developed, their utility for studying alveolar disease
etiology may be restricted. The COVID-19 syndrome is captured by the SARS-CoV-2 MA10
model, which includes a spectrum of morbidity and mortality determined by host genetics and
increasing age, as well as severe clinical characteristics of Acute Lung Injury/Acute Respiratory
Distress Syndrome (ALI/ARDS) and related lung function deficits. The lung pathology for SARSCoV-2 MA10 was established to quantify ALI and ARDS pathological aspects in SARS-CoV and
MERS-CoV [157] mouse models. Our data show MA10 replicated rapidly and caused interstitial
pneumonia like symptoms with robust infiltration of leucocytes in aged BALB/c mice. Clinical
features of COVID-19 in people were identical to those reported in these animals. Testing of
vaccines and treatments against SARS-CoV-2 has been delayed due to the limited availability of
transgenic mice models that can be infected with the SARS-CoV-2 virus [157]. Because older
people are more susceptible to SARS-CoV-2, using aged BALB/c or C57BL/6J mice provides a
simple and reliable way to assess COVID-19 vaccination efficacy.

Furthermore, telomeric disturbances and oxidative stress are prevalent in senescent cells,
activating signaling pathways such as nuclear factor B (NF-kB) and enhancing the production of
cytokines and chemokines [158]. In addition, pathogenic processes can exacerbate the
inflammatory response by releasing pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs) as people age [159]. Inflammatory mediators
such as prostaglandin E2, IL-6, and TNF- are released during cytomegalovirus (CMV) infection,
affecting 40–100% of the world's population, demonstrating the pathogen's crucial role in
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inflammation. Additionally, a strong interaction of viral S protein of SRAS-CoV-2 and TLR4
suggests that SARS-CoV-2 can directly activate proinflammatory pathways [160]. The
accumulation of NLRP3 puncta was found in monocytes infected in vitro with SARS-CoV-2, and
the same was seen in mononuclear cells recovered from COVID-19 patients, showing activation
of the inflammasome pathway.
Our data demonstrate a significantly high viral load in day 3 lungs of six-month and 20month-old mice. Both age groups showed increased virus titer, a little bit higher at 20 months;
however, not much difference between the two groups. Aged mice lungs showed abundant
leucocyte infiltration and hemorrhage at day 3 pi. The inflammatory genes IL-6, TNF-a, and CCL2 expression were comparatively higher in 20 months old than six months old. Interestingly the
mRNA expression of IFN-a was contrary as it was upregulated in six months old than 20 months
old mice. It has been reported that SARS-CoV-1 N protein interacts with TRIM25 to prevent IFN1 generation via RIG-I [161]. A balanced production of IFN-I has also been documented in
COVID-19 patients, and it appears to be related to disease severity [162, 163]. Furthermore,
SARS-CoV-2 infection causes a decrease in IFN-I and interferon-stimulated gene expression
[130]. Due to poor expression of TLR7 and TLR9 in old people, the population of Plasmacytoid
Dendritic Cells (pDCs), which is one of the key strategies for fighting viral infections, is
diminished and has less potential for IFN-secretion when stimulated with influenza virus.
Unpublished data from our lab showed upregulated genes associated with TLR, RIG-I and cell
death pathways. In addition, due to defective IFN transcription, elderly human monocytes produce
an imbalanced amount of IFN-I and IFN-III in response to influenza infection. These findings
imply that a diminished IFN-I response in advanced age may play a role in COVID-19 clinical
outcomes due to its diminished aid in virus clearance.
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The natural killer (NK) cell response is weakened in the elderly. In the absence of
stimulation, NK cells produced by older persons produce less IFN-a, which helps to explain why
they are more susceptible to viral infections at this age [164]. An animal model of influenza
infection reported a decrease in NK cells in the lungs, with decreased potential for IFN-a
production and degranulation [165]. Similarly, following SARS-CoV-2 infection, clinical
observations of individuals with COVID-19 demonstrated a dramatic decline in this cell type.
Furthermore, NK cells have been demonstrated to move to the lungs in a BALB/c senescent mouse
model of SARS-CoV-1 infection [166], indicating that these cells may play a role in coronavirus
infection pathogenesis.
These data suggest that innate immune cell malfunction connected to immunosenescence
may play a role in COVID-19 pathogenesis in the elderly, either by promoting a less effective
infection-fighting response and/or favoring an enhanced inflammatory response.
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7.1

OTHER SIGNIFICANT CONTRIBUTIONS

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2)
replication and attenuates inflammation in human cells
Abstract: SARS-COV-2 has recently emerged as a new public health threat. Herein, we

report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells
at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction
in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression
of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a
useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, antiinflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are
warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2
associated disease.
7.2

SARS-CoV-2 Variants of Concern Infect the Respiratory Tract and Induce
Inflammatory Response in Wild-Type Laboratory Mice
Abstract: The emergence of new severe acute respiratory syndrome coronavirus-2 (SARS-

CoV-2) variants of concern pose a major threat to public health, due to possible enhanced
virulence, transmissibility and immune escape. These variants may also adapt to new hosts, in part
through mutations in the spike protein. In this study, we evaluated the infectivity and pathogenicity
of SARS-CoV-2 variants of concern in wild-type C57BL/6 mice. Six-week-old mice were
inoculated intranasally with a representative virus from the original B.1 lineage, or the emerging
B.1.1.7 and B.1.351 lineages. We also infected a group of mice with a mouse-adapted SARS-CoV2 (MA10). Viral load and mRNA levels of multiple cytokines and chemokines were analyzed in
the lung tissues on day 3 after infection. Our data show that unlike the B.1 virus, the B.1.1.7 and
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B.1.351 viruses are capable of infecting C57BL/6 mice and replicating at high concentrations in
the lungs. The B.1.351 virus replicated to higher titers in the lungs compared with the B.1.1.7 and
MA10 viruses. The levels of cytokines (IL-6, TNF-α, IL-1β) and chemokine (CCL2) were
upregulated in response to the B.1.1.7 and B.1.351 infection in the lungs. In addition, robust
expression of viral nucleocapsid protein and histopathological changes were detected in the lungs
of B.1.351-infected mice. Overall, these data indicate a greater potential for infectivity and
adaptation to new hosts by emerging SARS-CoV-2 variants.
7.3

Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2Expressing Mice
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the

current pandemic, resulting in millions of deaths worldwide. Increasingly contagious variants of
concern (VoC) have fueled recurring global infection waves. A major question is the relative
severity of the disease caused by previous and currently circulating variants of SARS-CoV-2. In
this study, we evaluated the pathogenesis of SARS-CoV-2 variants in human ACE-2-expressing
(K18-hACE2) mice. Eight-week-old K18-hACE2 mice were inoculated intranasally with a
representative virus from the original B.1 lineage or from the emerging B.1.1.7 (alpha), B.1.351
(beta), B.1.617.2 (delta), or B.1.1.529 (omicron) lineages. We also infected a group of mice with
the mouse-adapted SARS-CoV-2 (MA10). Our results demonstrate that B.1.1.7, B.1.351 and
B.1.617.2 viruses are significantly more lethal than the B.1 strain in K18-hACE2 mice. Infection
with the B.1.1.7, B.1.351, and B.1.617.2 variants resulted in significantly higher virus titers in the
lungs and brain of mice compared with the B.1 virus. Interestingly, mice infected with the
B.1.1.529 variant exhibited less severe clinical signs and a high survival rate. We found that
B.1.1.529 replication was significantly lower in the lungs and brain of infected mice in comparison
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with other VoC. The transcription levels of cytokines and chemokines in the lungs of B.1- and
B.1.1.529-infected mice were significantly less when compared with those challenged with other
VoC. Together, our data provide insights into the pathogenesis of previous and circulating SARSCoV-2 VoC in mice.
7.4

Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity
against influenza and SARS-CoV-2 viruses
Abstract: Several approaches have produced an effective vaccine against severe acute

respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the influence of immune responses
induced by other vaccinations on the durability and efficacy of the immune response to SARSCoV-2 vaccine is still unknown. We have developed a hybrid vaccine for SARS-CoV-2 and
influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with
glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 S1 RBD fused to GM-CSF as an
adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and
incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid
vaccine induced a strong antibody response and protected mice from both influenza virus and
mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung
viral titers compared to naive mice. These results suggest that the hybrid vaccine strategy is a
promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV2 infections.
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8.1.1

SUMMARY

SARS-CoV-2 infection of mouse brain

Our study shows that direct infection of CNS cells and the inflammatory response are
important in triggering SARS-CoV-2-induced lethality in K18-hACE2 mice. The inducyttion of
cytokines/chemokines, infiltration of leukocytes into the perivascular space and parenchyma, and
cell death are characetristics of a virus infection of the CNS. In our analysis, SARS-CoV-2 viral
antigen was identified throughout the brain, including the cortex, cerebellum, and hippocampus.
Peak viral levels in the brain, immune cell infiltration, and CNS cell death were correlated with
the onset of severe disease in SARS-CoV-2-infected animals. The highest virus titers in the brains
were 1000 times greater than in the lungs, showing that SARS-CoV-2 has a large replicative ability
in the brain. The brain showed a 10- to 50-fold higher levels of cytokine and chemokine mRNAs
than the lungs, indicating that neuroinflammation had a role in clinical disease in these mice. We
found significant infectious virus titers in the olfactory system and brains of all the moce mice. On
days 5 and 6, the inflammatory reaction in the brain was more prominent than in the lungs. In
humans, COVID-19 illness is characterized by changes in smell and taste [8,41]. SARS-CoV-2
proteins were found in endothelial cells inside the olfactory bulb by pathological analysis of human
COVID-19 autopsy tissues [41,42]. The presence of virus replication in these tissues shows that
SARS-CoV-2 can infect the olfactory bulb and subsequently propagate throughout the brain by
infecting connecting brain neuron axons. This hypothesis is supported by earlier research showing
that neurotropic coronaviruses infect olfactory neurons and then go to the brain via axonal
transport [8,43].
Many viruses have been found to enter the CNS through olfactory sensory neurons,
including HSV-1, Nipah virus, rabies virus, Hendra virus, and influenza A virus [44,45].
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Disruption of the blood–brain barrier is another way for a virus to get entry to the brain (BBB).
However, no virus was found in the serum of infected mice at any point after infection, implying
that BBB disruption plays only a minor role in SARS-CoV-2 neuroinvasion. After infection with
SARS-CoV-1 or SARS-CoV-2, little or no virus was identified in the blood of K18-hACE2 mice
[22,23]. In conclusion, we discovered that intranasal SARS-CoV-2 infection induces severe
neurological illness in K18-hACE2 mice. Under the conditions utilized, our findings show that the
CNS is the primary target of SARS-CoV-2 infection in K18-hACE2 mice, and that brain infection
results in immune cell infiltration, inflammation, and cell death.
8.1.2

SARS-CoV-2 infection of mouse neurons

We showed that SARS-CoV-2 can infect neuronal cells from hACE2-K18 mice and cause
infection. Inflammatory and immunological genes were increased in neurons and mice brain in
response to infection. Furthermore, we discovered that SARS-CoV-2 infection increased genes
involved in the necroptotic pathway (ZBP1, MLKL, RIPK3, and caspase-8) in neurons and mouse
brain, implying that necroptosis may have an important role in the pathophysiology of SARSCoV-2 infection in the CNS. Some COVID-19 patients have had SARS-CoV-2 infection detected
in their brains [12,13]. In human neural progenitor cells and brain organoids, SARS-CoV-2 has
also been shown to proliferate and cause cell death [19,20]. In addition, dsRNA was found in
SARS-CoV-2-infected neuronal bodies and axons. In non-hACE2-expressing mouse neurons,
however, virus replication was restricted. One of the pathophysiological markers of the severe
consequences associated with SARS-CoV-2 infection is a cytokine storm [30,31]. Increased TNFand IL-6 levels have been linked to poor illness outcomes in several studies [32,33]. We show that
SARS-CoV-2 infection causes elevation of innate immune and inflammatory genes such as TNFand IL-6 in K18-hACE2 mouse brains [28]. Similarly, SARS-CoV-2-infected neuron cells showed
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a considerable rise in the production of IL-6, TNF-, CXCL10, and CCL2. These inflammatory
genes may excite glial cells, increasing neuroinflammation, and/or trigger subsequent cell-death
signaling pathways in neurons, resulting in neuronal death [34,35]. TNF- is known to be a
significant inducer of neuronal injury in a variety of neurodegenerative illnesses, including
cerebral ischemia, spinal cord injury, multiple sclerosis, and viral infections, such as HIVassociated dementia [33,36]. Both CXCL10 and CCL2 are significant chemokines that have a role
in leukocyte infiltration into the CNS following viral infection [35]. During virus infections, ZBP1
is one of the cytoplasmic sensors that regulates cell death and inflammation [37,38,39,40], and it
begins RHIM-dependent activation of RIPK3-dependent necroptosis. Necroptosis is an
inflammatory cell death triggered by phosphorylation of RIPK3, which activates the pseudo-kinase
MLKL, which oligomerizes and ruptures the plasma membrane, causing cell death [41,42].
Necroptosis inhibits virus multiplication by eradicating virus-infected cells and activating innate
and adaptive immunity. Inflammatory cytokines and damage-associated molecular patterns are
released as a result of this process, resulting in widespread inflammation [38,39,43]. After SARSCoV-2 infection, we discovered considerable overexpression of the necroptotic genes ZBP1,
MLKL, and RIPK3 in neuronal cells and animal brains. To explain the role of ZBP1 in SARSCoV-2 pathogenesis, more research is needed. SARS-CoV-2 replicates robustly in neuronal
preparations produced from K18-hACE2 mice, according to our findings. The virus infection of
neuronal cultures causes up-regulation of genes implicated in the innate immune response,
inflammation, and cell death, much as it does in SARS-CoV-2-infected K18-hACE2 mouse brains.
8.1.3

SARS-CoV-2 infection of wild-type mice

Our study also shows that SARS-CoV-2 variants can infect wild-type laboratory mice. The
B.1 virus did not infect C57BL/6 mice, but the B.1.351 and B.1.1.7 viruses did. Increased cytokine
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and chemokine levels, as well as leukocyte infiltration in the lungs, were seen in B.1.351- and
B.1.1.7-infected animals. Wild-type mice are not vulnerable to SARS-CoV-2 infection because
the first SARS-CoV-2 strains did not use murine ACE-2 as a receptor [8,9]. The mouse-adapted
strain of SARS-CoV-2 (MA10) produces infection, inflammation, and pneumonia in BALB/c mice
[11]. When compared to the Wuhan reference sequence, MA10 includes many alterations,
including the N501Y mutation in the RBD of the spike protein, which is likewise found in the
B.1.351 and B.1.1.7 variations [6,7]. These alterations in the spike protein's RBD may have
increased the binding affinity for the natural mouse ACE-2 receptor, allowing the variations to
reproduce more effectively in mice. Despite the fact that both B.1.351 and B.1.1.7 viruses were
capable of replicating in the lungs of mice, inoculation with the B.1.351 virus resulted in a much
larger viral load in the lungs than inoculation with the B.1.1.7 virus. Aside from the N501Y
mutation, many amino acid alterations have been hypothesized to be important for SARS-CoV-2
adaption in mouse species, including K417N, E484K, Q493H/K, and Q498H. The occurrence of
E484K and K417N mutations in B.1.351 has been demonstrated to boost infectivity, and E484K
has also been identified as an immunological escape mutation that develops during antibody
exposure [28]. This corresponds to our finding that the B.1.351 virus multiplied at a greater rate
than the B.1.1.7 virus. It's probable that mice with co-morbid illnesses including old age, diabetes,
and hypertension will have more severe symptoms. The capacity of SARS-CoV-2 variations to
reproduce and cause inflammation in wild-type mice will aid investigations employing transgenic
mouse strains to test therapeutic treatments and pathogenesis. These findings suggest that emergent
SARS-CoV-2 variants may be able to adapt to new animal species.
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8.1.4

Differential pathogenesis of SARS-CoV-2 infection in mice

SARS-CoV-2 evolves rapidly as the viral genome accumulates mutations, resulting in
several variants of concern (VoC) [4,5,10]. Most K18-hACE2 mouse research have used the
original SARS-CoV-2 virus strains, and just a few investigations have used emergent VoC. Our
findings show that the pathogenicity of SARS-CoV-2 in K18-hACE2 mice is VoC-dependent,
with the alpha, beta, and delta variants having the highest pathogenicity. In comparison to the B.1
lineage, we identified considerably greater virus titers in the lungs and brains of mice infected with
the B.1.1.7, B.1.351, and B.1.617.2 variations. In mice, however, the omicron form replicated
much less efficiently than the other SARS-CoV-2 variants. The modifications in the spike protein's
RBD may have increased the ACE2 receptor's binding affinity, allowing the variations to
reproduce more rapidly in mice. Indeed, our findings show that SARS-CoV-2 variants B.1.1.7 and
B.1.351, which contain the N501Y and E484K mutations, cause significant pathogenicity in K18hACE2 mice. In comparison to other SARS-CoV-2 variations, mice infected with the omicron
variant showed minimal illness despite having the highest number of mutations that could allow
for more efficient binding to ACE2. Epidemiological evidence also suggests that the omicron virus
infects humans less severely than the original strains and other VoC [29]. Overall, our findings
show that SARS-CoV-2 pathogenicity in K18-hACE2 mice is VoC-dependent, with the alpha,
beta, and delta variants having the highest pathogenicity and the omicron variant having the lowest.
8.1.5

Efficacy of Influenza and SARS-CoV-2 hybrid vaccine in mice

The combination of COVID-19 and seasonal influenza will produce high morbidity and
mortality, placing a pressure on the health system. Due to the logistical challenges of immunizing
with two vaccines each year, the notion of a combination vaccine is very appealing [167]. We've
shown that a hybrid vaccination based on influenza VLPs can provide effective protection against
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SARS-CoV-2 and influenza viruses. The antigen carrying VLPs are connected to cytokine
adjuvants in our vaccine platform (7). Antigens and biological adjuvants are delivered to the
immune system in a particulate form in this method. The hybrid vaccination elicited similar levels
of antibody response when administered subcutaneously or intramuscularly. Even 6 months after
vaccination, neutralizing antibody titers against inactivated influenza A/PR8 (H1N1) remain
robust, showing the longevity of the anti-influenza immune response induced by hybrid vaccine.
A comparison analysis of GPI-RBD-GM-CSF and GPI-RBD was not performed in this study to
demonstrate the contribution of GM-CSF as an adjuvant in VLP vaccination. Furthermore, our
research only looked at the RBD domain of the SARS-CoV-2 S protein, rather than the entire S
protein, which could limit the scope of the protective immune response. Finally, our findings
suggest that influenza VLP-based delivery of SARS-CoV-2 RBD protein combined with cytokine
adjuvants can be used to develop multivalent vaccines that target the various virus strains currently
found in the ongoing SARS-CoV-2 pandemic.
8.1.6

SARS-CoV-2 infection in aged mice

To investigate acute lung injury in the elderly, we used old BALB/c mice to imitate the
disease caused by SARS-CoV-2. Our findings suggest that acute lung injury and inflammatory
immune responses in MA10 infected old BALB/c mice lungs were similar to the clinical
symptoms of human illnesses. It has been suggested that a cytokine storm is involved in the
pathogenesis of severe COVID-19 cases. The levels of many cytokines and chemokines have been
found to be increased after SARS-CoV-2 infection [129, 130], and increased IL-6 level have been
correlated with severe disease outcomes [131, 132].
In aged human population a low-grade pro-inflammatory state, with a rise in serum
inflammatory mediators such as IL-6, IL-1RA, TNF-, IL-1, and C-reactive protein, is a prominent
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hallmark of the immunosenescence process [168, 169]. During the aging process, a low-grade
inflammatory condition is known as "inflammaging" is linked to a reduced ability to mount
effective immune responses [169].
The SARS-CoV-1 N protein has been found to interact with TRIM25, preventing IFN-1
production via RIG-I [161]. In COVID-19 patients, imbalanced IFN-I production has been
observed, and it appears to be linked to disease severity [162, 163]. Furthermore, in response to
influenza infection, older human monocytes produce an imbalanced amount of IFN-I and IFN-III
due to faulty IFN transcription. These findings suggest that in advanced age, a reduced IFN-I
response may have a role in COVID-19 clinical outcomes due to its reduced ability to help virus
clearance.
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